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1Experimental
S1
Total Synthesis of Azolemycin A and Related Compounds.
1) Experimental details.
General:
Room temperature refers to ambient temperature (20-22 °C) and 0 °C refers to an ice slush
bath. Heated experiments were conducted using thermostatically controlled oil baths.
Reactions were monitored by thin layer chromatography (TLC) using aluminium backed
silica 60 (F254) plates, visualised using UV254 nm and potassium permanganate as
appropriate. Silica column chromatography was carried out routinely using 40-60 Å silica
gel.
All the reagents and solvents used were purchased from the Sigma-Aldrich, Alfa-Aesar, TCI,
Bachem or Fluorochem Chemical Company and were used as received unless stated
otherwise. Dry THF, dry toluene and dry CH2Cl2 were prepared by storing over 3 Å
molecular sieves as described by Williams and Lawton,1 and degassed with N2 before use.
Dry DMSO was distilled off CaH2 onto 3 Å molecular sieves. pH2 buffer was made by
dissolving 0.75 M of Na2SO4 and 0.25 M H2SO4.
1H- and 13C-NMR spectra were recorded on a Bruker AVII-700 MHz, AVIII-600 MHz,
DRX-500 MHz or DPX-400 MHz Fourier transform spectrometer at room temperature unless
stated otherwise. Chemical shifts are quoted in parts per million (ppm) downfield from
tetramethylsilane. Solvents were used as an internal standard when assigning NMR spectra
(δH: CDCl3 7.26 ppm, CD3OD 3.31 ppm, d6 -DMSO-D6 2.50 ppm, D2O 4.79 ppm; δC: CDCl3
77.1 ppm, CD3OD 49.0 ppm, d6 -DMSO-D6 39.5 ppm). Coupling constants (J) are quoted in
Hertz (Hz). Coupling constants are rounded to the nearest 0.5 Hz for spectra recorded on the
AVIII-600 MHz, DRX-500 MHz or DPX-400 MHz machines. Coupling constants recorded
on the AVII-700 MHz machine are rounded to the nearest 0.1 Hz. Abbreviations used in the
descriptions of spectra are as follows; s = singlet, d = doublet, t = triplet, q = quartet, quin. =
quintet, sept. = septet, oct. = octet, m = multiplet, br = broad, i = ipso, o = ortho, m = meta, p
= para, ax. = axial and eq. = equatorial. 13 C-NMR spectra were recorded with broadband
proton decoupling and spectra were assigned on the basis of COSY, PENDANT, HMQC and
HMBC spectra. In aromatic characterisations, the ipso carbon is taken to be the carbon
bonded to the group with the highest molecular weight
2Infrared spectra were recorded on a Nicolet Avatar 320 FT-IR spectrophotometer using EZ
OMNIC software package 1, Bruker ALPHA Platinum ATR spectrophotometer or Perkin
ELMER Spectrum 100 FT-IR spectrophotometer using OPUS software and are quoted in
wavenumber (cm-1).
Optical rotations were recorded on an Optical Activity Ltd. AA-1000 millidegree auto-
ranging polarimeter (using the sodium D line; 589 nm) and [α]Ds are given in units of 10-1deg
cm2 g-1. The samples were made using spectroscopic grade MeOH, CHCl3 or H2O.
ESI mass spectra were obtained on a Bruker Esquire 2000 mass spectrometer or an Agilent
6130B single Quad (ESI). HR ESI spectra were obtained by Dr Lijiang Song, Mr Philip
Aston or Dr Rebecca Wills using a Bruker micro-TOF ESI attached to a time of flight (TOF)
analyser.
Melting points for solid crystalline products were determined on a Stuart Scientific SMP10
Digital Melting Point Apparatus, with three runs of each compound, and a range given in ˚C 
rounded to the nearest degree. They are uncorrected. CHN elemental analyses were carried
out by Warwick Analytical Services.




Method modified from literature procedure by Garner et al.2 A solution of di-tert-butyl
dicarbonate (112 g, 512 mmol) in dioxane (300 mL) was added dropwise to a stirred and
cooled solution of L-valine (50.0 g, 427 mmol) in aqueous NaOH solution (1 M, 875 mL) at 0
°C. The pH of the solution was adjusted to 9 using aqueous NaOH solution and the reaction
mixture was allowed to reach room temperature overnight. The pH was adjusted to between 9
and 10, and the reaction mixture extracted with diethyl ether (3 x 250 mL). The aqueous
phase was acidified to pH 2 with concentrated H2SO4 and extracted with EtOAc (5 x 100
mL). The combined organic extracts were washed with saturated aqueous NaCl solution (100
mL), dried over Na2SO4 and concentrated in vacuo to give the protected amino-acid as bright
white crystals (87.5 g, 403 mmol, 94 %); m.p. 76 - 78 °C, (lit.3 77 - 78 °C); 25][ D +6.6 (c =
1.1, CHCl3), (lit. 4 23][ D +11.7 (c = 2.35, CHCl3); υ max/cm-1 (neat) 3320 (NH), 2967 (OH),
1711 (acid C=O), 1640 (amide C=O), 1509 (NH); δH (400 MHz, CDCl3) 9.15 (1H, br.s.,
major and minor rotamer CO2H), 6.21 (1H, d, J 6.5 Hz, minor rotamer NHCH), 5.08 (1H, d,
J 9.0 Hz, major rotamer NHCH), 4.25 (1H, dd, J 9.0, 4.5 Hz, major rotamer NHCH), 4.13 -
3.93 (1H, m, minor rotamer NHCH), 2.29 – 2.13 (1H, m, major and minor rotamer CH(CH-
3)2), 1.47-1.40 (9H, m, major and minor rotamer C(CH3)3), 0.99 (1H, d, J 7.0 Hz, major and
minor rotamer CH(CH3)2), 0.93 (1H, d, J 7.0 Hz, major and minor rotamer CH(CH3)2); δC
(100 MHz, CDCl3) 176.8 (CO2H), 155.8 (CONH), 80.0 (C(CH3)3), 58.4 (CHNH), 30.9
(CH(CH3)2), 28.3 (C(CH3)3), 19.0, 17.4 (CH(CH3)2); m/z (ESI+) 240.1 ([M+Na]+, 100.0%);
HR ESI, m/z = 240.1208 (C10H19NO4Na requires M+Na = 240.1206). The data are consistent
with that previously reported.5
N-tert-Butoxy-L-serine 9
A solution of di-tert-butyl dicarbonate (25.0 g, 115 mmol) in dioxane (75 mL) was added
dropwise to a solution of L-serine (10.0 g, 95.2 mmol) in aqueous NaOH solution (1M, 195
mL, 195 mmol) at 0 °C. Following complete addition, the pH of the reaction mixture was
adjusted to pH 9 - 10 and it was stirred at room temperature overnight to give a white
suspension with a pH of 7 - 8. The pH was adjusted to 9 - 10 to give a clear, colourless









4aqueous phase was acidified to pH 2 buffer and extracted with EtOAc (4 x 100 mL). The
organic extracts were combined, washed with saturated aqueous NaCl solution (100 mL),
dried over Na2SO4 and concentrated in vacuo to give protected amino acid 9 as a colourless
oil (18.7 g, 91.1 mmol, 80 %); 27][ D -4.5 (c = 1.3, H2O), (lit.6
25][ D -7.6 (c = 2.6, H2O)); υ
max/cm-1 (neat) 3333.7 (O-H), 1686 (C=O), 1512 (N-H); δH (400 MHz, CDCl3) 6.67 (1H,
br.s., major and minor rotamer, CO2H), 5.89 (1H, d, J 7.0 Hz, major and minor rotamer, NH),
4.40 - 4.30 (1H, m, NHCH, major rotamer), 4.28 - 4.17 (1H, m, NHCH, minor rotamer), 4.05
(1H, dd, J 11.0, 3.0 Hz, major and minor rotamer, CHCH2), 3.85 (1H, dd, J 11.5, 3.0 Hz,
major and minor rotamer, CHCH2), 1.44 (9H, s, major and minor rotamer, C(CH3)3); δC (100
MHz, CDCl3) 154.1 (CO2H), 156.2 (CO2tBu), 80.5 (C(CH3)3), 63.0 (NHCH), 55.6 (CH2OH),
28.3 (C(CH3)3; m/z (ESI+) 228.0 ([M+Na] 100%); HR ESI, m/z = 228.0841, (C8H15NO5Na
requires M+Na = 228.0842). The data are consistent with that previously reported.7
(S)-3-(tert-Butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid 10
Method modified from literature procedure of Trajkovic et al.8 A solution of N-tert-
butyloxycarbonyl-L-serine 9 (13.3 g, 64.8 mmol), dimethoxypropane (64.0 g, 520 mmol) and
toluene sulphonic acid monohydrate (1.11 g, 6.47 mmol) in CH2Cl2 (75 mL) was heated to
reflux for 2 hours. After cooling to room temperature, the reaction mixture was concentrated
in vacuo and the residue was partitioned between water (150 mL) and EtOAc (100 mL). The
separated organic phase was washed with water (50 mL) and saturated aqueous NaCl solution
(50 mL), dried over Na2SO4 and concentrated in vacuo. The protected amino-acid 10 was
obtained, after drying under high vacuum, as a low melting point yellow solid (12.7 g, 51.8
mmol, 80 %); m.p. <30°C; 25][ D -58.2 (c = 1.20, CHCl3), (lit.9 for opposite enantiomer
24][ D
+ 63.1 (c = 1.10, CHCl3); υ max/cm-1 (neat) 3307 (O-H), 1687 (C=O), 1646 (C=O); δH (400
MHz, CDCl3) 8.59 (1H, br. s., major and minor rotamer CO2H), 4.49 (1H, dd, J 6.5, 2.0 Hz,
minor rotamer CHCH2), 4.37 (1H, dd, J 7.0 Hz, 3.0 Hz, major rotamer CHCH2), 4.20 - 4.13
(1H, m, major and minor rotamer CHCH2), 4.09 (1H, td, J 9.0, 2.5 Hz, CHCH2), 1.64 (3H, s,
major rotamer C(CH3)2), 1.59 (3H, s, 3H, s, minor rotamer C(CH3)2), 1.51 (3H, s, 3H, s,
major rotamer C(CH3)2), 1.47 (12H, s, 3H, s, major rotamer C(CH3)2, major rotamer
C(CH3)3), 1.40 (9H, s, major rotamer C(CH3)3); δC (100 MHz, CDCl3) 176.3, 175.1 (major
and minor rotamer CO2H), 152.7, 151.3 (major amd minor rotamer CO2tBu), 95.2 (major and
minor rotamer C(CH3)2), 82.9, 81.6 (major and minor rotamer C(CH3)3), 66.2, 65.8 (major
and minor rotamer CHCH2), 59.1 (major and minor rotamer CHCH2), 28.3 (major and minor
rotamer C(CH3)3), 24.9, 24.3 (major and minor rotamer C(CH3)2); m/z (ESI+) 268.1 ([M+Na]
5100%); HR ESI, m/z = 268.1147, (C11H19NO5Na requires M+Na = 268.1155). Spectroscopic
data are consistent with that previously reported.10
Dipeptide 11
A solution of the acid 10 (15.5 g, 62.9 mmol) and HOBt (88%, 1.45 g, 9.44 mmol) in EtOH
(300 mL) was stirred at room temperature for 15 minutes. To this was added a solution of L-
threonine methyl ester hydrochloride (11.7 g, 69.2 mmol) in EtOH (100 mL) and the mixture
was cooled to 0-5 °C. N-Methylmorpholine (22.0 mL, 202 mmol) was added over 5 minutes,
and the reaction was stirred at 0-5 °C for 15 minutes. EDCI (14.4 g, 75.5 mmol) was added in
one portion, and the reaction mixture was allowed to reach room temperature overnight. The
reaction was acidified with pH 2 buffer and was reduced in vacuo. EtOAc (250 mL) was
added, the mixture was vigorously agitated and the phases were separated. The organic phase
was washed with pH 2 buffer (100 mL), water (100 mL), saturated aqueous NaHCO3
solution, and saturated aqueous NaCl solution (100 mL), dried over Na2SO4 and concentrated
in vacuo to give dipeptide 10 as an orange crystalline solid (19.1 g, 53.0 mmol, 84 %); m.p.
77 - 80 °C; 25][ D -61.0 (c = 1.10, CHCl3); υ max/cm-1 (neat) 3437 (O-H), 1735 (ester C=O),
1655 (amide C=O), 1524 (N-H); δH (500 MHz, CDCl3) 7.27 (1H, s, major and minor rotamer
N10-H), 4.55 (1H, dd, J 9.0, 2.0 Hz, major and minor rotamer C8-H), 4.49 - 4.00 (4H, m,
major and minor rotamer C11-H, C29-H2, C30-H), 3.73 (3H, s, OCH3), 2.74 (1H, br. s., C30-
OH), 1.85 – 1.36 (17H, m, major and minor rotamer C(CH3)3, C(CH3)2), 1.17 (3H, d, J 6.5
Hz, major and minor rotamer C30-CH3); δC (125 MHz, CDCl3) 173.4, 171.0 (major and
minor rotamer C9, C12), 153.1, 151.8 (major and minor rotamer CO2tBu), 95.12, 94.6 (major
NS minor rotamer C(CH3)2), 81.4 (major and minor rotamer C(CH3)3), 68.2, 67.7 (major and
minor rotamer C8-H), 67.1, 65.5 (major and minor rotamer C29-H2), 60.8, 60.2 (major and
minor rotamer C30-H), 57.4 (major and minor rotamer C11-H), 52.5 (major and minor
rotamer OCH3), 28.2, 26.6 (major and minor rotamer C(CH3)3, C(CH3)2), 19.9 (major and
minor rotamer C30-CH3); m/z (ESI+) 383.1 ([M+Na] 100%), 361.1 ([M+H] 60%); HR ESI,
m/z = 383.1785, (C16H28N2O7Na requires M+Na = 383.1789).
6Oxazole Methyl Ester 5 and Alkene 13
Method modified from literature procedure of Doi et al.11 A solution of the dipeptide 11 (15.9
g, 44.2 mmol) in dry CH2Cl2 (220 mL) was cooled to 0 – 5 °C under a nitrogen atmosphere.
Diisopropylethylamine (30.0 mL, 176 mmol) and dry DMSO (16.0 mL, 225 mmol) were
added sequentially, followed by the addition of SO3.pyr (21.1g, 133 mmol) over 5 minutes.
The reaction mixture was stirred at 0 – 5 °C for 3 hours, then poured into ice cold pH 2 buffer
(200 mL) and stirred for 5 minutes. The phases were separated and the aqueous phase was
further extracted with dichloromethane (2 x 10 mL). The combined organic extracts were
dried over Na2SO4 and ketone 12 obtained by silica chromatography (50% EtOAc: pet ether)
as a yellow oil (10.7 g, 29.8 mmol, 68 %). This was used immediately.
Oxazole 5 prepared according to the method of Bagley et al.12 Iodine (14.9 g, 58.6 mmol) and
triethylamine (16.8 mL, 120 mmol) were added sequentially to an ice cold solution of
triphenylphosphine (15.4 g, 58.6 mmol) in CH2Cl2 (150 mL) under a nitrogen atmosphere. A
solution of the ketone (10.5 g, 29.3 mmol) in CH2Cl2 was added dropwise and the reaction
mixture was allowed to reach room temperature overnight. The mixture was concentrated in
vacuo and the residue was partitioned between EtOAc (150 mL) and pH 2 buffer (100 mL).
The phases were separated and the organic phase was washed with pH 2 buffer (100 mL),
water (100 mL) and saturated aqueous NaCl solution (100 mL), dried over Na2SO4 and
concentrated in vacuo. Oxazole 5 was obtained by silica chromatography (25% to 50%
EtOAc: pet. ether) as a pale yellow solid (4.15 g, 12.2 mmol, 28 % over 2 steps); m.p. 60 - 63
°C; 25][ D -87.1 (c = 1.10, CHCl3); υ max/cm-1 (neat) 1698 (C=O), 1609 (C=N); δH (400 MHz,
CDCl3) 5.15 - 5.07 (1H, m, minor rotamer C8-H), 4.99 (1H, dd, J 6.0 Hz, 3.0 Hz, major
rotamer C8-H), 4.25 - 4.04 (2H, m, major and minor rotamer C29-H2), 3.88 (3H, s, major
rotamer OCH3), 3.85 (3H, br. s., minor rotamer OCH3), 2.60 (3H, s, major rotamer C30-
CH3), 2.57 (3H, br. s., minor rotamer C30-CH3), 1.71 (3H, s, major rotamer C(CH3)2), 1.67
(3H, br. s., minor rotamer C(CH3)2), 1.58 - 1.52 (3H, m, minor rotamer C(CH3)2), 1.46 (9H,
br. s., minor rotamer C(CH3)3), 1.28 (9H, s, major rotamer C(CH3)3); δC (100 MHz, CDCl3)
162.6 (major and minor rotamer C10), 161.1 (major and minor rotamer C9), 156.2 (major and
minor rotamer C30), 151.2 (major and minor rotamer CO2tBu), 127.5 (major and minor
rotamer C11), 65.1 (major and minor rotamer C(CH3)2), 81.1, 80.5 (major and minor rotamer
C(CH3)3), 67.5, 67.4 (major and minor rotamer C29-H2), 55.1 (major and minor rotamer C8-
H), 52.3, 51.9 (major and minor rotamer OCH3), 28.3 (major and minor rotamer C(CH3)3),

























7m/z (ESI+) 363.1 ([M+Na] 100%), 341.1 ([M+H] 60%); HR ESI, m/z = 363.1526, (C16H24N-
2O6Na requires M+Na = 363.1527). In some cases this method led to the formation of a
significant amount of elimination product 20 (~20 % of isolated product, inseparable from
desired oxazole 5), identifiable by 1H spectroscopy; δH (400 MHz, CDCl3) 6.83 (1H, q, J 7.0
Hz, C30-H), 1.79 (3H, d, J 7.0 Hz, C30-CH3).
Asymmetric Dihydroxylation of Alkene 13
Both methods of production of oxazole 5 occasionally provided an inseparable mixture of the
oxazole 5 and alkene 13. The alkene was removed using a method modified from literature
procedure of a Sharpless et al.13 K₃[Fe(CN)₆] (2.01 g, 6.13 mmol), K2CO3 (0.85 g, 6.1
mmol), (DHQD)2PHAL (0.02 g, 0.02 mmol) and methane sulphonamide (0.19 g, 2.0 mmol)
were added to a solution of the mixture of oxazole 5 and alkene 13 (2.10 g; approximately
0.70 g, 2.0 mmol alkene 13) in tBuOH:H2O (1: 1, 50 mL) at room temperature. After 5
minutes, K2OsO4·2H2O (0.008 g, 0.02 mmol) was added and the reaction mixture was stirred
at room temperature for 24 hours. Sodium sulfite (~0.1 g) was added and the mixture was
stirred for a further 30 minutes. The phases were separated and the aqueous phase was further
extracted with EtOAc (3 x 10 mL). The combined organic phases were washed with pH 2
buffer (10 mL), water (10 mL) and saturated aqueous NaHCO3 solution (10 mL), dried over
Na2SO4 and concentrated in vacuo. Silica chromatography (50 % EtOAc: pet. ether) gave
only the desired oxazole (0.67 g, 1.98 mmol). All characterisation data was consistent to that
previously obtained.
Preparation of activated MnO2
Prepared according to the method set out by Fatiadi.14 A solution of KMnO4 (26.3 g, 167
mmol) in water (500 mL) was added slowly to a solution of manganese sulfate monohydrate
(42.3 g, 250 mmol) in water (720 mL) at 60 ˚C in a 2L beaker. The solution was stirred at 60 
°C for 1 hour. After cooling to room temperature, the suspension was filtered. The filtercake
was washed with water (~2L) until the pH of the aqueous washes was neutral. The filtercake
was dried under vacuum over silica for to give a dense black solid (86.1 g), to give the
unactivated MnO2 with ~68% associated water. This was activated immediately before use
according to the method of Goldman.15
8Tripeptide Oxazole 14
Oxazole methyl ester 5 (3.05 g, 8.96 mmol) was dissolved in a solution of methanolic
hydrochloric acid (4 M, 21.5 mL) and stirred at room temperature for 18 hours. The reaction
mixture was concentrated in vacuo to give the crude deprotected amine as hydrochloride salt
8, which was used without further purification assuming quantitative yield.
A solution of Boc-Val-OH (2.83 g, 13.4 mmol) and HOBt (88 %, 0.32g, 2.1 mmol) in EtOH
(50 mL) were stirred at room temperature for 15 minutes. To this was added a solution of the
crude amine (8.96 mmol) in EtOH (40 mL) and the reaction mixture was cooled to 0-5 °C. N-
Methylmorpholine (4.70 mL, 43.0 mmol) was added and the reaction was stirred at 0-5 °C
for 15 minutes. EDCI (3.08 g, 16.1 mmol) was added, and the reaction mixture allowed to
reach room temperature overnight. The reaction mixture was acidified with pH 2 buffer,
filtered, and the filtrate was concentrated in vacuo. The residue was partitioned between pH 2
buffer (50 mL) and EtOAc (100 mL) and the phases were separated. The organic phase was
washed with pH 2 buffer (25 mL), water (25 mL), saturated aqueous NaHCO3 solution (25
mL) and saturated aqueous NaCl solution (25 mL), dried over Na2SO4 and concentrated in
vacuo. The pure tripeptide, 14, was obtained by silica chromatography (EtOAc) as a bright
white crystalline solid (2.05 g, 5.13 mmol, 57 %; also performed with 1.68 g, 88 %); m.p. 99
– 100 ˚C; 25][ D -47 (c = 0.52, CHCl3); υ max/cm-1 (neat) 3326 (NH), 3306 (OH), 1721 (ester
C=O), 1687 (amide C=O), 1519 (NH);1H NMR (400 MHz, CDCl3) 7.50 (1H, d, J 8.0 Hz,
N7-H), 5.43 (1H, d, J 8.5 Hz, N4-H), 5.22 (1H, dt, J 8.0, 4.0 Hz, C8-H), 4.23 - 4.16 (1H, m,
CH2OH), 4.02 – 3.96 (2H, m, C5-H, CH2OH), 3.95 – 3.86 (1H, m, CH2OH), 3.80 (3H, s,
OCH3), 2.51 (3H, s, oxazole CH3), 2.11 - 2.00 (1H, m, CHCH3), 1.35 (9H, s, C(CH3)3), 0.90
(3H, d, J 7.0 Hz, CH(CH3)2), 0.86 (3H, d, J 6.5 Hz, CH(CH3)2); δC (175 MHz, CDCl3) 172.1
(C6), 162.4 (C12), 159.8 (C9), 156.9 (C30), 156.2 (CO2tBu), 127.3 (C11), 80.2 (C(CH3)3),
63.1 (C29-H2), 60.2 (C5-H), 52.0 (OCH3), 49.3 (C8-H), 30.8 (C26-H), 28.3 (C(CH3)3), 19.2
(C28-H3), 17.8 (C28-H3), 12.0 (C30-CH3); m/z (ESI+) 422.1 ([M+Na] 100%); HR ESI, m/z =
400.2087, (C18H30N3O7 requires M+H = 400.2078).
9Bisoxazole 4
(Diethylamino)sulfur trifluoride (1.22 mL, 9.24 mmol) was added dropwise to a solution of
the tripeptide 14 (2.05 g, 5.13 mmol) in dry CH2Cl2 (55 mL) at – 78 °C under a nitrogen
atmosphere. The recation mixture was stirred at -78 °C for 2 hours, then at room temperature
for 30 minutes. The reaction was quenched with saturated aqueous NaHCO3 solution (55 mL)
and stirred for 15 minutes. The phases were separated and the organic phase was further
extracted with CH2Cl2 (2 x 20 mL). The combined organic phases were dried over Na2SO4
and concentrated in vacuo. The crude oxazoline was used immediately without further
purification
A suspension of MnO2 (prepared by the method of Fatiadi,14 17.8 g, 103 mmol) in toluene
(100 mL) was heated to reflux with azeotropic water removal using Dean-Stark apparatus
until no more water could be removed. A solution of the oxazoline (5.13 mmol) in toluene
(10 mL) was added and the reaction heated to reflux with azeotropic water removal for 6
hours. After cooling to room temperature, an acidic solution of sodium sulphite (1.5 g
Na2SO3/1 g MnO2 in 5 volumes of water, acidified to pH 5 with concentrated H2SO4) was
added to the reaction mixture and the pH of the aqueous phase was adjusted to 5 and stirred
until dissolution of the suspension. The phases were separated and the aqueous phase was
acidified to pH 2 and extracted with EtOAc (3 x 50 mL). The combined organic phases were
washed with water (100 mL), saturated aqueous NaHCO3 solution (100 mL), and saturated
aqueous NaCl solution (100 mL), dried over Na2SO4 and concentrated in vacuo. Bisoxazole 4
was obtained by silica chromatography (50 % EtOAc: pet. ether) as a bright white solid (0.53
g, 1.4 mmol, 27% over 2 steps); m.p. 128 - 130 °C; 24][ D -47 (c = 0.53, CHCl3);  υ max/cm-1
(neat) 3349 (NH), 2964 (aromatic C-H), 1712 (ester C=O), 1683 (amide C=O), 1519 (NH);
δH (400 MHz, CDCl3) 8.25 (1H, s, C29-H), 5.30 (1H, d, J 9.0 Hz, N4-H), 4.82 (1H, dd, J
9.0, 6.5 Hz, C5-H), 3.93 (3H, s, OCH3), 2.70 (3H, s, C30-CH3), 2.22 (1H, m, C26-H), 1.46 -
1.39 (9H, m, C(CH3)3), 0.95 (3H, d, J 7.5 Hz, C26(CH3)2), 0.93 (3H, d, J 7.5 Hz,
C26(CH3)2); δC (100 MHz, CDCl3) 165.4 (C6), 164.5 (CO2Me), 156.5 (C30), 155.3 (CONH),
153.0 (C9), 138.8 (C29-H), 129.8 (C8), 128.3 (C11), 80.0 (C(CH3)3), 54.3 (C5), 52.0
(OCH3), 33.0 (C26), 28.3 (C(CH3)3), 18.7, 18.0 (C26(CH3)2), 12.0 (C30-CH3); m/z (ESI+)
402.0 ([M+Na] 100%); HR ESI, m/z =402.1640, (C18H25N3O6Na requires M+Na =402.1636).
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Preparation of Model Isoleucine Oxazoles
N-tertButoxycarbonyl-L-isoleucine
Prepared as for Boc-Val-OH, 7, but using L-isoleucine (10.0 g, 76.2 mmol). The Boc-
protected product was obtained as a clear, colourless oil (14.5 g, 62.5 mmol, 82 %); 25][ D +
3.80 (c =1.01, MeOH); (lit.16 20][ D +3.9 (c = 2.00, MeOH); υ max/cm-1 (neat) 3321 (NH), 2967
(OH ), 1708 (acid C=O), 1503 (NH); δH (400 MHz, CDCl3) 10.36 (1H, br. s., major and
minor rotamer CO2H), 6.16 (1H, br. s, minor rotamer CHNH), 5.13 (1H, d, J 8.5 Hz, major
rotamer CHNH), 4.25 (1H, dd, J 8.5, 4.5 Hz, major rotamer CHNH), 4.12 – 4.06 (1H, m,
major rotamer CHNH), 1.99 - 1.81 (1H, m, CHCH3), 1.53 - 1.42 (10H, m, C(CH3)3,
CH2CH3), 1.28 – 1.08 (1H, m, CH2CH3), 0.96 (3H, d, J 6.5 Hz, CHCH3), 0.92 (3H, t, J 7.5
Hz, CH2CH3); δC (100 MHz, CDCl3) 177.2 (CO2H), 155.8 (CO2tBu), 80.0 (C(CH3)3), 58.1
(CHNH), 37.7 (CHCH3), 28.3 (C(CH3)3), 24.9 (CH2CH3), 15.5 (CHCH3), 11.6 (CH2CH3);
m/z (ESI+) 230.1 ([M-H] 100%); HR ESI, m/z = 254.1350, (C11H21NO4Na requires M+Na
=254.1363). The data are consistent with that previously reported.16
N-tertButoxycarbonyl-L-isoleucine and N-tertButoxycarbonyl-D-allo-isoleucine
Prepared as for Boc-Val-OH, 10, but using a mixture of l-isoleucine and d-allo-isoleucine
(0.50 g, 3.8 mmol). The Boc-protected product was obtained as a clear, colourless oil (0.77 g,
3.3 mmol, 88 %, 73: 27 mix of (2S, 3S) and (2R, 3S), calculated by 1H NMR); υ max/cm-1
(neat) 3314 (NH), 2966 (OH ), 1711 (acid C=O), 1506 (NH); δH (400 MHz, CDCl3) 8.71
((2S, 3S), 1H, br. s., major and minor rotamer CO2H; (2R, 3S), 1H, br. s., major and minor
rotamer CO2H), 6.17 ((2S, 3S), 1H, d, J 7.0 Hz, minor rotamer CHNH), 6.08 ((2R, 3S), 1H, d,
J 7.0 Hz, minor rotamer CHNH), 5.06 ((2S, 3S), 1H, d, J 8.5 Hz, major rotamer CHNH), 5.00
((2R, 3S), 1H, d, J 9.0 Hz, major rotamer CHNH), 4.41 ((2R, 3S), 1H, dd, J 9.5, 4.0 Hz, major
rotamer CHNH), 4.30 ((2S, 3S), 1H, dd, J 9.0, 4.5 Hz, major rotamer CHNH), 4.24 - 4.17
((2R, 3S), 1H, m, minor rotamer CHNH), 4.13 - 4.05 ((2S, 3S), 1H, m, minor rotamer
CHNH), 2.03 - 1.83 ((2S, 3S), 1H, m, major and minor rotamer CHCH3; (2R, 3S), 1H, m,
major and minor rotamer CHCH3), 1.45 ((2S, 3S), 10H, m, major and minor rotamer
CH2CH3, C(CH3)3; (2R, 3S), 10H, m, major and minor rotamer CH2CH3, C(CH3)3), 1.31 -










rotamer CH2CH3), 0.99 - 0.87 ((2S, 3S), 6H, m, major and minor rotamer CH2CH3, CHCH3;
(2R, 3S), 1H, m, major and minor rotamer CH2CH3, CHCH3); δC (100 MHz, CDCl3) 177.8,
177.3 ((2S, 3S), CO2H; (2R, 3S), CO2H), 155.8 ((2S, 3S), CO2 tBu; (2R, 3S), CO2tBu), 80.1
((2S, 3S), C(CH3)3; (2R, 3S), C(CH3)3), 59.1, 57.8 ((2S, 3S), CHNH; (2R, 3S), CHNH), 37.7,
37.4 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 28.3 ((2S, 3S), C(CH3)3; (2R, 3S), C(CH3)3), 26.3,
24.9 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 15.5 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 11.7
((2S, 3S), CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 230.1 ([M+H] 100%); HR ESI, m/z =
230.1385, (C11H20NO4 requires M+H = 230.1398).
N-tertButoxycarbonyl-L-isoleucyl-L-serine methyl ester
Acetyl chloride (5.20 mL, 73.2 mmol) was added dropwise with stirring to MeOH (30 mL) at
0 °C. The mixture was allowed to reach room temperature and L-serine (1.30 g, 12.2 mmol)
was added and the mixture was heated to reflux for 18 hours. The reaction mixture was
concentrated in vacuo to give the crude methyl ester as the hydrochloride salt, which was
used without further purification assuming quantitative yield.
A solution of Boc-L-isoleucine (0.93 g, 4.0 mmol) and HOBt (88 %, 90mg, 0.60 mmol) in
EtOH (13 mL) was stirred at room temperature for 15 minutes, then cooled to 0-5°C. To this
was added a solution of the crude serine methyl ester (4.42 mmol) and N-methyl morpholine
(1.40 mL, 12.9 mmol) in EtOH (9 mL) and the resulting colourless solution stirred at 0-5°C
for 15 minutes. EDCI (0.92 g, 4.8 mmol) was added and the reaction mixture was allowed to
reach room temperature overnight to give a pale yellow solution. This was acidified using pH
2 buffer and N-methyl morpholine hydrosulfate was removed by filtration. The filtrate was
concentrated in vacuo, and extracted with EtOAc (4 x 10 mL). The combined organic extracts
were washed with pH 2 buffer (10 mL), water (10 mL), saturated aqueous NaHCO3 solution
(10 mL) and saturated aqueous NaCl solution (10 mL), dried over Na2SO4 and concentrated
in vacuo to give dipeptide as a white powdery solid (0.79 g, 2.4 mmol, 60 %); m.p. 83 – 85
˚C; 25][ D  -19 (c = 0.26, MeOH); υ max/cm-1 (neat) 3323 (NH), 1748 (ester C=O), 1688 (amide
C=O), 1520 (NH); δH (400 MHz, CDCl3) 7.20 (1H, d, J 7.5 Hz, Ser NHCH), 5.38 (1H, d, J
8.0 Hz, Ile NHCH), 4.67 (1H, ddd, J 8.0, 4.0, 3.0 Hz, Ser NHCH), 4.01 - 3.85 (3H, m, Ile
NHCH, CH2OH), 3.76 (3H, s, OCH3), 1.88 - 1.74 (1H, m, CHCH3), 1.61 - 1.50 (1H, m,
CH2CH3), 1.42 (9H, s, C(CH3)3), 1.21 - 1.08 (1H, m, CH2CH3), 0.95 (3H, d, J 6.5 Hz,
CHCH3), 0.89 (3H, t, J 7.5 Hz, CH2CH3); δC (100 MHz, CDCl3) 172.3 (CO2CH3), 170.8
(CONH), 156.3 (CO2tBu), 80.2 (C(CH3)3), 62.7 (CH2OH), 59.4 (Ile CHNH), 57.9 (Ser
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CHNH), 52.6 (OCH3), 37.2 (CHCH3), 28.3 (C(CH3)3), 24.8 (CH2CH3), 15.4 (CHCH3), 11.3
(CH2CH3); m/z (ESI+) 355.1 ([M+Na] 100%); HR ESI, m/z = 355.1823, (C15H28N2O6Na




Prepared as for the single diastereoisomer using L-serine methyl ester hydrochloride (3.44
mmol) and a mixture of Boc-L-isoleucine and Boc-D-allo-isoleucine (0.72 g, 3.1 mmol), N-
methyl morpholine (1.0 mL, 10 mmol), HOBt (88 %, 0.07 g, 0.5 mmol), EDCI (0.72 g, 3.8
mmol) and EtOH (17 mL) to give the dipeptide as a bright white solid (0.79 g, 2.4 mmol, 76
%; 78: 22 mix of (2S, 3S) and (2R, 3S) diastereomers by 1H NMR); υ max/cm-1 (neat) 3322
(NH), 1748 (ester C=O), 1689 (amide C=O), 1522 (NH); δH (400 MHz, CDCl3) 7.26 (1H, d,
J 8.0 Hz, (2S, 3S), Ser CHNH; 1H, d, J 8.0 Hz, (2R, 3S), Ser CHNH), 5.41 (1H, d, J 9.0 Hz,
(2S, 3S), Ile CHNH), 5.20 (1H, d, J 7.5 Hz, (2R, 3S), Ile CHNH), 4.66 (1H, dt, J 7.5, 3.5 Hz,
(2S, 3S), Ser CHNH; 1H, dt, J 7.5, 3.5 Hz, (2R, 3S), Ser CHNH), 4.19 - 4.11 (1H, m, (2R,
3S), Ile CHNH), 3.98 (1H, dd, J 8.5, 7.5 Hz, (2S, 3S), Ile CHNH), 3.98 – 3.83 (2H, m, (2S,
3S), CH2OH; 2H, m, (2R, 3S CH2OH), 3.75 (3H, m, (2S, 3S), OCH3; 3H, m, (2R, 3S),
OCH3), 2.06 - 1.94 (1H, m, (2R, 3S), CHCH3), 1.86 – 1.74 (1H, m, (2S, 3S), CHCH3), 1.65 -
1.48 (1H, m, (2S, 3S), CH2CH3; 1H, m, (2R, 3S), CH2CH3), 1.42 (9H, s, (2R, 3S), C(CH3)3),
1.40 (9H, s, (2S, 3S), C(CH3)3), 1.29 – 1.07 (1H, m, (2S, 3S), CH2CH3; 1H, m, (2S, 3S),
CH2CH3), 0.97 - 0.85 (1H, m, (2S, 3S), CHCH3,CH2CH3; 1H, m, (2S, 3S), CHCH3, CH2CH3);
δC (100 MHz, CDCl3) 172.3 ((2S, 3S), CO2H; (2R, 3S), CO2H), 171.0, 170.8 ((2S, 3S),
CONH; (2R, 3S), CONH), 156.3 ((2S, 3S), CO2tBu; (2R, 3S), CO2tBu), 80.4, 80.2 ((2S, 3S),
C(CH3)3; (2R, 3S), C(CH3)3), 62.6 ((2S, 3S), CH2OH; (2R, 3S), CH2OH), 59.4, 58.4 ((2S, 3S),
Ile NHCH; (2R, 3S), Ile NHCH), 54.7 ((2S, 3S), Ser NHCH; (2R, 3S), Ser NHCH), 52.7, 52.6
((2S, 3S), OCH3; (2R, 3S), OCH3), 37.3, 37.0 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 28.3 ((2S,
3S), C(CH3)3; (2R, 3S), C(CH3)3), 24.8 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 15.4, 14.2
((2S, 3S), CHCH3; (2R, 3S), CHCH3), 11.7, 11.2 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3); m/z
(ESI+) 355.1 ([M+Na] 100%); HR ESI, m/z = 355.1839, (C15H28N2O6Na requires M+Na =
355.1840).
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(2S, 3S) Isoleucine Oxazole
(Diethylamino)sulfur trifluoride (0.17 mL, 1.3 mmol) was added to solution of the N-
tertButoxycarbonyl-L-isoleucyl-L-serine methyl ester (0.31 g, 0.92 mmol) in dry CH2Cl2 (8.5
mL) at -78 °C under a nitrogen atmosphere. The reaction mixture was stirred at -78 °C for 1.5
hours, and at room temperature for 30 minutes. The reaction was quenched with saturated
aqueous NaHCO3 solution (10 mL) and stirred for 15 minutes. The phases were separated
and the aqueous phase was further extracted with CH2Cl2 (2 x 5 mL). The combined organic
phases were dried over Na2SO4 and concentrated in vacuo to give the crude oxazoline as a
yellow oil that was used immediately assuming quantitative yield.
MnO2 (prepared by the method of Carpino,18 5 x mass oxazoline, 1.25 g) was added to a
solution of the oxazoline (0.25 g, 0.92 mmol) in dry toluene (12 mL) under a nitrogen
atmosphere. The reaction was heated to reflux with azeotropic removal of water over 3Å
molecular sieves for 20 hours. After cooling to room temperature, the mixture was filtered
through celite. The celite was washed with EtOAc (5 x 5 mL) and the filtrate was
concentrated in vacuo. (2S, 3S) Isoleucine oxazole was obtained by silica chromatography
(50% EtOAc: pet. ether) as a white solid (7 mg, 0.02 mmol, 2 %); 25][ D -19 (c = 0.64,
CHCl3); υ max/cm-1 (neat) 3326 (NH), 2972 (aromatic C-H), 1727 (ester C=O), 1698 (amide
C=O), 1529 (NH); δH (400 MHz, CDCl3) 8.18 (1H, s, oxazole C-H), 5.33 (1H, d, J 9.0 Hz,
NHCH), 4.86 (1H, dd, J 9.0, 6.0 Hz, NHCH), 3.91 (3H, s, OCH3), 2.01 - 1.88 (1H, m,
CHCH3), 1.51 – 1.39 (10H, m, CH2CH3, C(CH3)3), 1.24 – 1.10 (1H, m, CH2CH3), 0.90 (3H,
t, J 7.0 Hz, CH2CH3), 0.86 (3H, d, J 7.0 Hz, CHCH3); δC (100 MHz, CDCl3) 164.1 (C1),
160.6 (CO2Me), 154.2 (CO2tBu), 142.8 (oxazole C-H), 132.1 (C2), 79.0 (C(CH3)3), 52.3
(CHNH), 51.2 (OCH3), 38.5 (CHCH3), 28.7 (C(CH3)3), 24.0 (CH2CH3), 14.3 (CHCH3),10.4
(CH2CH3); m/z (ESI+) 335.1 ([M+Na] 100%); HR ESI, m/z = 335.1572, (C15H24N2O5Na
requires M+Na = 335.1577). This compound is known, but no characterisation data has been
reported.19
(2S, 3S) and (2R, 3S) Oxazole
Prepared as for the (2S, 3S) Oxazole using a diastereomeric mix of N-tertbutoxycarbonyl-L-
isoleucyl- and N-tertbutoxycarbonyl-L-allo-isoleucyl-L-serine methyl ester (0.39 g, 1.2
mmol), (diethylamino)sulfur trifluoride (0.22 mL, 1.6 mmol) and CH2Cl2 (11 mL) to give the
14
oxazoline. The oxazole was prepared as for the single diastereomer with MnO2 (2.2 g) and
dry toluene (10 mL). Additional MnO2 (0.85 g) and dry toluene (5 mL) were added after 2
hours at reflux, and the reaction mixture was heated to reflux for a further 7 hours. The
cooled reaction mixture was filtered over celite, and the celite washed with EtOAc (5 x 10
mL). The filtrate was concentrated in vacuo and the oxazole was obtained by silica
chromatography (50% EtOAc: pet. ether) as a white solid (3 mg, 0.09 mmol, 1 %; 72: 28 mix
of (2S, 3S) and (2R, 3S) diastereomers by 1H NMR): δH (400 MHz, CDCl3) 8.18 (1H, s, (2S,
3S CC-H; 1H, s, (2R, 3S), CC-H), 5.32 (1H, d, J 9.0 Hz, (2S, 3S), NHCH), 5.27 (1H, d, J 9.5
Hz, (2S, 3S), NHCH), 4.95 (1H, dd, J 9.5 Hz, 5.0 Hz, (2R, 3S), NHCH), 4.86 (1H, dd, J 9.0
Hz, 6.5 Hz, (2S, 3S), NHCH), 3.91 (3H, s, (2S, 3S), OCH3; 3H, s, (2R, 3S), OCH3), 2.02 –
1.88 (1H, m, (2S, 3S), CHCH3; 1H, m, (2R, 3S), CHCH3), 1.50 – 1.39 (10H, m, (2S, 3S),
CH2CH3, C(CH3)3; 10H, m, (2R, 3S), CH2CH3, C(CH3)3), 1.23 – 1.10 (1H, d, J 7.0 Hz, (2S,
3S), CH2CH3; 1H, d, J 7.0 Hz, (2R, 3S), CH2CH3), 0.96 - 0.83 (6H, m, (2S, 3S), CHCH3,
CH2CH3; 6H, m, (2R, 3S), CHCH3, CH2CH3); δC (100 MHz, CDCl3) 165.2 ((2S, 3S), C1;
(2R, 3S), C1), 161.6 ((2S, 3S), CO2Me; (2R, 3S), CO2Me), 155.3 ((2S, 3S), CO2tBu; (2R, 3S),
CO2tBu), 143.8 ((2S, 3S), CC-H; (2R, 3S), CC-H), 133.2 ((2S, 3S), C2; (2R, 3S), C2), 80.1
((2S, 3S), C(CH3)3; (2R, 3S), C(CH3)3), 53.4, 52.7 ((2S, 3S), CHNH; (2R, 3S), CHNH), 51.6
((2S, 3S), OCH3; (2R, 3S), OCH3), 39.5, 39.3 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 28.3 ((2S,
3S), C(CH3)3; (2R, 3S), C(CH3)3), 25.9, 25.1 ((2S, 3S), CH2CH3); (2R, 3S), CH2CH3), 15.2,
14.5 (2S, 3S), CHCH3; (2R, 3S), CHCH3), 11.6, 11.4 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3);
m/z (ESI+) 335.1 ([M+Na] 100%); HR ESI, m/z = 335.1582, (C15H24N2O5Na requires M+Na
= 335.1577).
Bisoxazole Acid
Lithium hydroxide (0.13 g, 5.3 mmol) and water (3 mL) were added to a solution of the
bioxazole methyl ester 4 (0.50 g, 1.3 mmol) in THF (3 mL) at room temperature. The
reaction was stirred for 4 hours and then acidified using pH 2 buffer. The organic solvents
were removed in vacuo and the residue was partitioned between EtOAc (15 mL) and pH 2
buffer. The separated aqueous phase was further extracted with EtOAc (3 x 5 mL) and the
combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give a mix
of rotamers of acid as a white crystalline solid (0.46 g, 1.3 mmol, 95 %); m.p. 93 - 94 °C;
26][ D -45.0 (c = 1.05, CHCl3); υ max/cm-1 (neat) 3295 (NH), 2117 (OH), 1696 (acid C=O),
1509 (NH); δH (400 MHz, CDCl3) 8.29 (1H, s, C29-H), 7.68 (1H, br.s., major and minor
rotamer, CO2H), 6.38 (1H, d, J 6.0 Hz, minor rotamer N4-H), 5.46 (1H, d, J 9.5 Hz, major
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rotamer N4-H), 4.83 (1H, dd, J 9.5, 6.5 Hz, major rotamer C5-H), 4.71 - 4.59 (1H, m, minor
rotamer C5-H), 2.72 (3H, s, major and minor rotamer, C30-CH3), 2.21 (1H, oct., J 6.5 Hz,
major and minor rotamer, C26-H), 1.48 - 1.37 (9H, m, major and minor rotamer, C(CH3)3),
0.96 (3H, d, J 7.0 Hz, major and minor rotamer, C26(CH3)2), 0.92 (3H, d, J 7.0 Hz, major and
minor rotamer, C26(CH3)2); δC (100 MHz, CDCl3) 165.6, 165.4 (C6, CO2H), 157.3 (C30),
155.4 (CONH), 153.0 (C9), 139.1 (C29-H), 129.5 (C8), 128.1 (C9), 80.1 (C(CH3)3), 54.3
(C5), 32.8 (C26), 28.2 (C(CH3)3), 18.7, 18.0. (C26(CH3)2), 12.2 (C30-CH3): m/z (ESI+) 388.1
([M+Na] 100%); HR ESI, m/z =388.1474, (C17H23N3O6Na requires M+Na =388.1479).
Pentapeptide 15
Oxazole methyl ester 5 (0.67 g, 2.0 mmol) was added to methanolic hydrochloric acid
solution (4 M, 3 mL) and the reaction mixture was stirred at room temperature for 18 hours.
The solvent was removed in vacuo to give the crude deprotected amine as hydrochloride salt
8, which was used without further purification.
HOBt (88 %, 0.03 g, 0.2 mmol) was added to a solution of the bisoxazole (0.46 g, 1.3 mmol)
in EtOH (4 mL) and the mixture stirred at room temperature for 15 minutes. A solution of the
crude amine (2.0 mmol) in EtOH (3 mL) was added and the mixture cooled to 0 °C. N-
Methylmorpholine (0.58 mL, 5.3 mmol) was added and the solution was stirred at 0-5 °C for
15 minutes. EDCI (0.29 g, 1.5 mmol) was added and the reaction was stirred to room
temperature overnight. The reaction was acidified with pH 2 buffer and concentrated in
vacuo. The residue was partitioned between EtOAc (10 mL) and pH 2 buffer (10 mL) and the
phases were separated. The aqueous phase was further extracted with EtOAc (3 x 2 mL) and
the combined organic phases were washed with saturated aqueous NaCl solution (10 mL),
dried over Na2SO4 and concentrated in vacuo. Pentapeptide 15 was obtained by silica
chromatography (EtOAc) as yellow solid (0.50 g, 0.77 mmol, 64 %); m.p. 104 - 105 °C;
25][ D -29 (c = 0.54, CHCl3); υ max/cm-1 (neat) 3320 (NH), 2972 (OH), 1726 (acid C=O), 1683
(amide C=O), 1531 (NH); δH (400 MHz, CDCl3) 8.15 (1H, s, C29-H), 7.82 (1H, d, J 8.5 Hz,
N13-H), 5.46 (1H, dt, J 9.0, 4.5 Hz, C14-H), 5.41 (1H, d, J 9.0 Hz, N4-H), 4.86 – 4.79 (1H,
m, C5-H), 4.23 (1H, dd, J 11.5, 4.5 Hz, CH2OH), 4.05 (1H, dd, J 11.5, 4.5 Hz, CH2OH), 3.90
(3H, s, OCH3), 3.32 - 3.36 (1H, m, CH2OH), 2.71 (3H, s, C30-CH3), 2.61 (3H, s, C33-CH3),
2.26 - 2.17 (1H, m, C26-H), 1.43 (9H, s, C(CH3)3), 0.97 (2H, d, J 7.0 Hz, C26(CH3)2), 0.94
(3H, d, J 6.5 Hz, C26(CH3)2); δC (150 MHz, CDCl3) 165.8 (C6), 162.4 (CO2Me), 161.5
(C12), 159.8 (C15), 157.0 (C33), 155.4 (CO2tBu), 154.0 (C30), 152.2 (C9), 138.6 (C29-H),
16
129.8 (C8), 159.6 (C11), 127.4 (C17), 80.0 (C(CH3)3), 63.3 (CH2OH), 54.4 (C5), 52.0
(OCH3), 48.5 (C14), 33.0 (C26), 28.3 (C(CH3)3), 18.8, 18.1 (C26(CH3)2), 12.1 (C33-CH3),
11.8 (C30-CH3); m/z (ESI+) 570.2 ([M+Na] 100%); HR ESI, m/z =570.2172, (C25H33N5O9Na
requires M+Na =570.1270).
Pentapeptide Silyl Ether 16
Method modified from literature procedure of McKeever et al.20 Imidazole (0.19 g, 2.8
mmol) was added in one portion to a solution of alcohol 15 (0.75 g, 1.4 mmol) in dry DMF
(6.5 mL) under an atmosphere of nitrogen at 0 °C. The reaction mixture was stirred at 0 °C
for 5 minutes and tBuMe2SiCl (0.32 g, 2.10 mmol) was added in one portion. The ice bath
was removed and the reaction stirred at room temperature for 3 hours. The reaction mixture
was diluted with EtOAc (10 mL) and H2O (40 mL), and the phases were separated. The
aqueous phase was further extracted with EtOAc (5 x 10mL). The combined organic extracts
were washed with water (5 x 10 mL) and saturated aqueous NaCl solution (10 mL), dried
over NaSO4 and concentrated in vacuo. Protected alcohol 16 was obtained by silica
chromatography (1:1 EtOAc: pet. ether) as a bright white crystalline solid (0.57 g, 0.86
mmol, 62 %); m.p. 57 - 58 °C; 25][ D -1.1 (c = 0.37, CHCl3); υ max/cm-1 (neat) 3319 (NH),
1716 (ester C=O), 1672 (amide C=O), 1506 (NH), 836 (Si-C); δH (400 MHz, CDCl3) 8.16
(1H, s, C29-H), 7.74 (1H, d, J 8.5 Hz, N13-H), 5.42 (1H, dt, J 8.5, 5.0 Hz, C14-H), 5.29 (1H,
d, J 9.0 Hz, N4-H), 4.85 (1H, dd, J 8.5, 6.0 Hz, C5-H), 4.12 (1H, dd, J 10.0, 4.5 Hz, CH2OH),
4.00 (1H, dd, J 10.0, 5.5 Hz, CH2OH), 3.90 (3H, s, OCH3), 2.71 (3H, s, C30-CH3), 2.61 (3H,
s, C33-CH3), 2.28 - 2.20 (1H, m, C26-H), 1.45 (9H, s, OC(CH3)3), 0.98 - 0.94 (6H, m,
C26(CH3)2), 0.85 (9H, s, SiC(CH3)3), 0.02 (3H, s, SiCH3), 0.00 (3H, s, SiCH3); δC (100 MHz,
CDCl3) 165.6 (C6), 162.7 (CO2Me), 161.3 (C12), 160.2 (C15), 156.6 (C33), 155.3 (COtBu),
153.8 (C30), 152.0 (C9), 138.5 (C29-H), 130.1 (C8), 129.7 (C11), 127.6 (C17), 80.1
(C(CH3)3), 64.3 (C14-CH2), 54.3 (C5), 51.9 (CO2CH3), 48.9 (C13), 33.0 (C26), 28.3
(C(CH3)3), 25.7 (SiC(CH3)3), 18.7, 18.0 (C26(CH3)2), 17.9 (SiC(CH3)3), 12.0, 11.8 (C30-
CH3, C33-CH3), -5.4 (Si(CH3)2); m/z (ESI+) 684.3 ([M+Na] 100%); HR ESI, m/z =
684.3023, (C31H47N5O9SiNa requires M+Na = 684.3035).
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Thioamide Silyl Ether 17
Method modified from literature procedure of McKeever et al.20 Silyl ether 16 (0.50 g, 0.76
mmol) was dissolved in dry THF (10 mL) and dry toluene (6.5 mL) under nitrogen and
Lawesson’s reagent (0.34 g, 0.83 mmol) was added. The reaction was heated to reflux under
a nitrogen atmosphere for 44 hours, during which Lawesson’s reagent (1.08 g, 2.67 mmol)
and dry THF (15 mL) was added in 3 equal portions after 18, 24 and 40 hours. The reaction
mixture was cooled to room temperature and concentrated in vacuo. The residue was
partitioned between EtOAc (20 mL) and aqueous NaHCO3 solution (1: 1 saturated NaHCO3:
water, 20 mL). The separated aqueous phase was further extracted with EtOAc (3 x 5 mL).
The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The
protected thioamide 17 was obtained by silica chromatography (5 % acetone: toluene) as a
bright yellow oil (0.39 g, 0.58 mmol, 76 %); 22][ D +13 (c = 1.2, CHCl3); υ max/cm-1 (neat)
3320 (N-H), 1685 (ester C=O), 1504 (N-H), 1252 (C=S), 833 (Si-C); δH (400 MHz, CDCl3)
9.52 (1H, d, J 8.5 Hz, N13-H), 8.15 (1H, s, C29-H), 6.01 (1H, dt, J 8.5, 4.5 Hz, C14-H), 5.30
(1H, d, J 9.0 Hz, N4-H), 4.83 (1H, dd, J 9.0, 6.5 Hz, C5-H), 4.22 (1H, dd, J 10.5, 4.0 Hz,
C14-CH2), 4.07 (1H, dd, J 10.5, 5.5 Hz, C14-CH2), 3.88 (3H, s, OCH3), 2.88 (3H, s, C30-
CH3), 2.59 (3H, s, C33-CH3), 2.28 - 21 (1H, m, C26-H), 1.43 (9H, s, C(CH3)3), 0.96 (2H, d, J
7.0 Hz, C26(CH3)2), 0.94 (3H, d, J 6.5 Hz, C26(CH3)2), 0.84 - 0.87 (9H, m, SiC(CH3)3), 0.04
(3H, s, SiCH3), -0.01 (3H, s, SiCH3); δC (100 MHz, CDCl3) 186.4 (C12), 165.6 (C6), 162.6
(CO2Me), 159.5 (C15), 156.7 (C33), 155.4 (COtBu, C30), 150.6 (C9), 138.7 (C29-H), 134.2
(C11), 129.9 (C8), 127.6 (C17), 80.1 (C(CH3)3), 63.6 (C14-CH2), 54.3 (C5), 53.4 (C14), 51.9
(CO2CH3), 32.9 (C26), 28.3 (OC(CH3)3), 25.7 (SiC(CH3)3), 18.7, 18.1 (C26(CH3)2), 18.0
(SiC(CH3)3), 13.8 (C30-CH3), 12.0 (C33-CH3), -5.6 (Si(CH3)2); m/z (ESI+) 700.3 ([M+Na]
100%); HR ESI, m/z =700.2790, (C31H47N5O8SSiNa requires M+Na = 700.2807).
Thioamide 18
Bu4NF (1M solution in THF, 1.0 mL, 1.0 mmol) was added to the thioamide silyl ether 17
(0.34 g, 0.50 mmol) under a nitrogen atmosphere at 0 °C. The mixture was stirred at 0 °C for
1 hour to give a brown solution. The reaction mixture was concentrated in vacuo and the
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residue was partitioned between EtOAc (5 mL) and water (2 mL). The phases were separated,
and the organic phase was washed with water (2 x 2 mL), saturated aqueous NaCl solution (2
mL), dried over Na2SO4 and concentrated in vacuo to give a yellow oil. Thioamide 18 was
obtained by silica chromatography (50 % EtOAc: petrol) as a yellow glassy solid (0.24 g,
0.45 mmol, 90 %); m.p. 127 - 129 °C; 27][ D -18 (c = 0.36, CHCl3); υ max/cm-1 (neat) 3340
(NH), 2972 (OH), 1708 (ester C=O), 1519 (NH), 1249 (C=S); δH (400 MHz, CDCl3) 9.56
(1H, d, J 8.0 Hz, N13-H), 8.17 (1H, s, C29-H), 6.15 (1H, dt, J 8.5, 4.5 Hz, C14-H), 5.53 (1H,
d, J 9.0 Hz, N4-H), 4.81 (1H, dd, J 8.5, 6.5 Hz, C5-H), 4.31 (1H, dd, J 11.5, 4.5 Hz, CH2OH),
4.16 (1H, dd, J 11.5, 4.0 Hz, CH2OH), 3.86 (3H, s, OCH3), 2.85 (3H, s, C30-CH3), 2.57 (3H,
s, C33-CH3), 2.27 – 2.14 (1H, m, C26-H), 1.40 (9H, s, C(CH3)3), 0.96 (3H, d, J 7.0 Hz,
C26(CH3)2), 0.92 (3H, d, J 6.5 Hz, C26(CH3)2); δC (100 MHz, CDCl3) 186.5 (C12), 165.6
(C6), 162.3 (C18), 159.2 (C15), 157.0 (C33), 155.6, 155.5 (C30, CO2tBu), 150.8 (C9), 138.9
(C29-H), 134.1 (C11), 129.6 (C8), 127.4 (C17), 80.0 (C(CH3)3), 62.5 (CH2OH), 54.5 (C5),
53.2 (C14), 51.9 (OCH3), 32.9 (C26), 29.3 (C(CH3)3), 18.8, 18.1 (C26(CH3)2), 13.9 (C30-
CH3), 12.0 (C33-CH3); m/z (ESI+) 586.2 ([M+Na] 100%); HR ESI, m/z = 586.1950,
(C25H33N5O8SNa requires M+Na = 586.1942).
Thiazole 19
A solution of the thioamide 18 (0.24 g, 0.46 mmol) in dry CH2Cl2 (5 mL) was cooled to -78
°C under a nitrogen atmosphere. (Diethylamino)sulfur trifluoride (0.11 mL, 0.80 mmol) was
added dropwise and the reaction mixture was stirred at -78 °C for 1 hour, then to room
temperature over 30 minutes. The reaction mixture was quenched with saturated aqueous
NaHCO3 solution (5 mL) and stirred for 15 minutes. The biphasic mixture was separated and
the aqueous phase was extracted with CH2Cl2 (2 x 5 mL). The combined organic phases were
dried over Na2SO4 and concentrated in vacuo to give the crude thiazoline as a bright orange
oil. This was used without further purification.
The thiazole was prepared using a method modified from the literature procedure of Videnov
et al.21 The solution of the crude thiazoline (0.46 mmol) in acetonitrile (1.5 mL), CCl4 (1.1
mL), pyridine (1.5 mL) was cooled to 0 °C under a nitrogen atmosphere and 1, 8-
Diazabicyclo[5.4.0]undec-7-ene (0.30 mL, 2.0 mmol) was added dropwise. The reaction was
allowed to reach room temperature overnight. The resulting brown suspension was
partitioned between pH 2 buffer (5 mL) and CH2Cl2 (5 mL) and the phases separated. The
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aqueous phase was further extracted with CH2Cl2 (3 x 5 mL), and the combined organic
phases were dried over Na2SO4 and concentrated in vacuo to give the crude thiazole. This
was purified by silica chromatography (50 % EtOAc: pet. ether) to give thiazole 19 as a
bright white solid (0.11 g, 0.20 mmol, 45 %); m.p. 206 - 209 °C; 26][ D -3.6 (c = 0.49, CHCl3);
υ max/cm-1 (neat) 3349 (NH), 1708 (ester C=O), 1686 (amide C=O), 1523 (NH); δH (400 MHz,
CDCl3) 8.22 (1H, s, C29-H), 8.09 (1H, s, C32-H), 5.32 (1H, d, J 9.0 Hz, N4-H), 4.85 (1H, dd,
J 8.5, 6.5 Hz, C5-H), 3.97 - 3.92 (3H, m, OCH3), 2.88 (3H, s, C30-CH3), 2.74 (3H, s, C33-
CH3), 2.22 (1H, s, C26-H), 1.44 (9H, s, C(CH3)3), 0.96 (3H, d, J 7.0 Hz, C26(CH3)2), 0.94
(8H, d, J 7.0 Hz, M11); δC (150 MHz, CDCl3) 165.6 (C6), 162.7 (C18), 162.0 (C12), 156.5
(C33), 155.4, 155.3 (CO2tBu, C15), 153.3 (C9), 148.2 (C30), 143.6 (C14), 138.6 (C29-H),
130.8 (C11), 130.0 (C8), 128.4 (C17), 120.5 (C32-H), 80.1 (C(CH3)3), 54.4 (C5-H), 52.1
(CO2CH3), 32.4 (C26-H), 28.3 (C(CH3)3), 18.8, 18.1 (C26(CH3)2), 12.2, 12.1 (C30-CH3,
C33-CH3); m/z (ESI+) 566.2 ([M+Na] 100%); HR ESI, m/z = 566.1679, (C25H29N5O7SNa
requires M+Na = 566.1680).
Tetrazole Carboxylic Acid 20
LiOH (80 mg, 3.5 mmol) was added to a stirred suspension of methyl ester 19 (0.19 g, 0.35
mmol) in MeOH (15 mL), THF (15 mL) and water (2.7 mL). After 18 hours at room
temperature, THF (5 mL), MeOH (5 mL) and CH2Cl2 (3 mL) were added to the suspension,
and the mixture stirred for a further 8 hours, until complete by TLC (EtOAc). The mixture
was acidified with pH 2 buffer, and the organics removed in vacuo. The mixture was
extracted with CH2Cl2 (5 x 3 mL), and the combined organics were dried over Na2SO4 and
concentrated in vacuo to give acid 20 as a bright white solid (0.17 g, 0.32 mmol, 92%); m.p.
208 - 210 °C; 24][ D  -54 (c = 0.25, MeOH); υ max/cm-1 (neat) 3332 (NH), 3120 (OH), 1685
(acid C=O), 1620 (amide C=O), 1518 (NH); δH (600 MHz, CDCl3) 8.23 (1H, s, C29-H), 8.11
(1H, s, C32-H), 5.86 (1H, br.s, minor rotamer N4-H), 5.40 (1H, d, J 9.5 Hz, major rotamer
N4-H), 4.86 (1H, dd, J 9.0, 6.5 Hz, major rotamer C5-H), 4.70 (1H, br. s., minor rotamer C5-
H), 2.88 (3H, s, C30-CH3), 2.77 (3H, s, C33-CH3), 2.35 - 2.18 (1H, m, C26-H), 1.54 - 1.37
(9H, m, C(CH3)3), 0.98 (3H, d, J 7.0 Hz, C26(CH3)2), 0.95 (3H, d, J 7.0 Hz, C26(CH3)2); δC
(150 MHz, CDCl3) 165.7 (C6), 165.2 (CO2H), 162.2 (C12), 157.3 (C33), 155.4, 155.3
(CO2tBu, C15), 153.3 (C30), 143.4 (C14), 140.23 (C29-H), 130.8 (C11), 129.9 (C8), 128.2
(C17), 120.8 (C32-H), 80.1 (C(CH3)3), 54.4 (C5-H), 33.0 (C26), 28.3 (C(CH3)3), 18.8, 18.1
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(C26(CH3)2), 12.3, 12.2 (C30-CH3, C33-CH3); m/z (ESI-) 528.0 ([M-H] 100%); HR ESI, m/z
= 552.1540, (C24H27N5O7SNa requires M+Na = 552.1523).
Hexapeptide 21
HOBt (88 %, 5 mg, 0.03 mmol) was added to a solution of carboxylic acid 20 (86 mg, 0.16
mmol) in EtOH (2 mL), and the reaction mixture was stirred for 15 minutes at room
temperature. To this was added a solution of L-isoleucine methyl ester hydrochloride (70 mg,
0.40 mmol) in EtOH (2 mL) and the mixture was cooled to 0-5 °C. N-Methyl morpholine
(0.11 mL, 1.05 mmol) was added and the mixture was stirred at 0-5 °C for 15 minutes. EDCI
(46 mg, 0.24 mmol) was added and the reaction mixture allowed to reach room temperature
overnight. The resulting dense white suspension was acidified with pH 2 buffer, and
extracted with EtOAc (5 x 5 mL). The combined organics were washed with saturated
aqueous NaCl solution (5 mL), dried over Na2SO4 and concentrated in vacuo to give the
crude hexapeptide. Hexapeptide 21 was obtained by silica chromatography (2% MeOH:
CH2Cl2) as a pale yellow crystalline solid (89 mg, 0.14 mmol, 84 %); m.p. 127 - 129 ˚C; 
24][ D -18 (c = 0.51, CHCl3); υ max/cm-1 (neat) 3305 (NH), 1742 (ester C=O), 1680, 1630
(amide C=O), 1510 (NH); δH (500 MHz, CDCl3) 8.23 (1H, s, C29-H), 8.00 (1H, s, C32-H),
7.51 (1H, d, J 9.0 Hz, N19-H), 5.33 (1H, d, J 10 Hz, N4-H), 4.87 (1H, dd, J 9.0, 7.0 Hz, C5-
H), 4.75 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.78 (3H, s, OCH3), 2.91 (3H, s, C30-CH3), 2.75
(3H, s, C33-CH3), 2.26 (1H, s, C35-H), 2.02 (1H, br. s., C26-H), 1.61-.1.56 (1H, m, C37-
H)1.46 (9H, s, C(CH3)3), 1.34 - 1.25 (1H, m, C37-H), 1.03 - 0.95 (9H, m, C26(CH3)2, C36-
H3, C38-H3); δC (125 MHz, CDCl3) 172.3 (C21), 165.6 (C6), 162.3 (C12), 161.6 (C18),
154.3 (C15), 153.6 (C33), 153.3 (C9), 148.2 (C30), 143.8 (C14), 139.0 (C29-H), 130.8
(C11), 130.0, 129.9 (C8, C17), 120.1 (C32-H), 80.1 (C(CH3)3), 56.2 (C20), 54.4 (C5), 52.1
(OCH3), 38.0 (C35), 33.1 (C26), 28.3 (C(CH3)3), 25.3 (C37), 18.8, 18.1 (C26(CH3)2), 15.6
(C36), 12.2, 11.9, 11.5 (C30-CH3, C33-CH3, C38). Missing one quaternary carbon; m/z




A solution of the Boc-protected hexapeptide 21 (89 mg, 0.14 mmol) in methanolic
hydrochloride (2M, 2.1 mL) was stirred at room temperature for 2 hours. The mixture was
concentrated in vacuo to give the deprotected amine hydrochloride salt as an amorphous
cream solid (80 mg, 0.14 mmol, 99 %); 28][ D  +3.50 (c = 0.495, MeOH); υ max/cm-1 (neat)
2966 (NH), 1738 (ester C=O), 1663, 1627 (amide C=O), 1512 (NH); δH (700 MHz, MeOD)
8.73 (1H, s, C29-H), 8.27 (1H, s, C32-H), 4.56 - 4.61 (2H, m, C5-H, C20-H), 3.80 - 3.76 (3H,
m, OCH3), 2.89 - 2.86 (3H, m, C30-CH3), 2.67 (3H, s, C33-CH3), 2.45 (1H, oct. J 6.5 Hz,
C26-H), 2.07 – 2.00 (1H, m, C35-H), 1.58 (1H, dqd, J 14.5, 7.5, 4.8 Hz, C37-H), 1.37 - 1.30
(1H, m, C37-H), 1.16 (3H, d, J 6.5 Hz, C26-CH3), 1.05 (3H, d, J 6.5 Hz, C26-CH3), 1.00
(3H, d, J 6.5 Hz, C36-H3), 0.98 (3H, t, J 7.5 Hz, C38-H3); δC (175 MHz, MeOD) 172.0
(C21), 162.0, 161.9 (C6, C12), 160.7 (C18), 154.7, 154.1, 153.1 (C15, C33, C9), 148.6
(C30), 143.8 (C14), 140.8 (C29-H), 130.4, 130.0, 129.9 (C8, C17, C11), 120.9 (C32-H), 56.4
(C20), 53.9 (C5), 51.2 (OCH3), 37.3 (C35), 33.1 (C26), 25.3 (C37), 17.4, 16.7 (C26(CH3)2),
14.6 (C36), 10.5, 10.4, 10.3 (C30-CH3, C33-CH3, C38); m/z (ESI+) 579.1 ([M+Na] 100%);
HR ESI, m/z = 557.2189, (C26H33N6O6S requires M-Cl = 557.217.
(S)-2-Hydroxy-3-methylbutanoic acid 22
Prepared according to the method of Bauer et al.22 A solution of L-valine (1.00 g, 8.54 mmol)
in dilute aqueous sulphuric acid (0.5M, 34.0 mL, 17.0 mmol) was cooled to 0 °C. A solution
of sodium nitrate (3.53 g, 51.2 mmol) in water (11.5 mL) was added dropwise, and the
reaction mixture was stirred at 0-5 °C for a further 30 minutes and at room temperature
overnight. The reaction mixture was extracted with Et2O (5 x 10 mL). The combined organic
extracts were washed with saturated aqueous NaCl solution (20 mL), dried over Na2SO4 and
concentrated in vacuo to give yellow crystals. These were recrystallised from pet. ether to
give hydroxyacid 22 as bright white crystals (0.31 g, 2.6 mmol, 31 %); m.p. 65 - 66 °C (lit.23
65 - 66 °C); 26][ D +14.0 (c = 1.01, CHCl3) (lit.22
26][ D +17.3 (c = 1.06, CHCl3); υ max/cm-1
(neat) 3414 (OH), 1703 (acid C=O); δH (400 MHz, CDCl3) 6.05 (1H, br.s, CO2H), 4.16 (1H,
d, J 3.5 Hz, CHOH), 2.17 (1H, septd, J 6.5, 3.5 Hz, CH(CH3)2), 1.07 (3H, d, J 6.5 Hz,
CH(CH3)2), 0.93 (3H, d, J 7.0 Hz, CH(CH3)2); δC (100 MHz, CDCl3) 179.4 (CO2H), 74.8
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(CHOH), 32.0 (CH(CH3)2), 18.8 (CH(CH3)2), 15.9 (CH(CH3)2); m/z (ESI-) 117.1 ([M-H]
100%); HR ESI, m/z = 117.0554, (C5H9O3 requires M-H = 117.0557); This data is
consistent with that previously reported.24
Heptapeptide 23
A solution of the (2S)-2-hydroxy-3-methylbutanoic acid, 22, (80 mg, 0.68 mmol) and HOBt
(88 %, 21 mg, 0.14 mmol) in EtOH (3 mL) was stirred at room temperature for 15 minutes
before being added to a solution of the hexapeptide hydrochloride salt (80 mg, 0.14 mmol) in
EtOH (2 mL). The reaction mixture was cooled to 0-5 °C and N-methylmorpholine (0.12 mL,
1.1 mmol) was added. After 15 minutes at 0-5 °C, EDCI (0.16 g, 0.68 mmol) was added and
the reaction mixture allowed to reach room temperature overnight. The mixture was acidified
with pH 2 buffer and EtOH removed in vacuo. The mixture was extracted with EtOAc (4 x 5
mL), and the combined organic extracts were washed with water (5 mL), saturated aqueous
NaHCO3 solution (5 mL), dried over Na2SO4 and concentrated in vacuo to give the crude
heptapeptide. The alcohol 23 was obtained by silica chromatography (98:2:0.2
EtOAc:MeOH:AcOH) as an amorphous solid (72 mg, 0.11 mmol, 81 %); 26][ D -50 (c = 0.53,
CHCl3); υ max/cm-1 (neat) 3432 (NH), 3265 (OH), 1740 (ester C=O), 1648 (amide C=O), 1507
(NH); δH (500 MHz, CDCl3) 8.20 (1H, s, C29-H), 7.97 (1H, s, C32-H), 7.61 (1H, d, J 9.5 Hz,
N4-H), 7.49 (1H, d, J 9.0 Hz, N19-H), 5.22 (1H, dd, J 9.5, 7.0 Hz, C5-H), 4.73 (1H, dd, J 9.0,
5.5 Hz, C20-H), 4.29 – 4.26 (1H, m, C2-H), 3.77 (3H, s, OCH3), 2.88 (3H, s, C30-CH3), 2.74
- 2.71 (3H, m, C30-CH3), 2.39 - 2.24 (2H, m, C23-H, C26-H), 2.05 - 1.96 (1H, m, 1H, m,
C35-H), 1.62 - 1.51 (1H, m, C37-H), 1.34 - 1.23 (1H, m, C37-H), 1.06 - 0.90 (18H, m, C24-
CH3, C25-CH3, C27-CH3, C28-CH3, C36-CH3, C38-CH3); δC (125 MHz, CDCl3) 173.4 (C3),
172.2 (C21), 165.6 (C6), 162.1 (C12), 161.6 (C18), 165.2 (C15), 153.6 (C22), 153.0 (C9),
148.3 (C30), 143.8 (C14), 138.5 (C29-H), 130.8 (C11), 129.9, 129.8 (C8, C17), 120.2 (C32-
H), 76.4 (C2-H), 56.2 (C20), 52.3, 52.1 (C5, OCH3), 38.0 (C35), 32.9, 31.7 (C23, C26), 25.3
(C37), 19.2, 19.0, 18.5, 15.6, 15.5 (C24, C25, C27, C28, C36) 12.1, 11.9, 11.5 (C30-CH3,
C33-CH3, C38); m/z (ESI+) 679.1 ([M+Na] 100%); HR ESI, m/z = 679.2528,
(C31H40N6O8SNa requires M+Na = 679.2521).
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Ketone 24
A solution of alcohol 23 (57 mg, 0.087 mmol) in dry CH2Cl2 (3 mL) and dry DMSO (0.06
mL) was cooled to 0-5°C under a nitrogen atomosphere. iPr2NEt (0.12 mL, 0.69 mmol) and
SO3.pyr (83 mg, 0.52 mmol) were added sequentially, and the reaction stirred at 0-5°C for 3
hours. The mixture was acidified with pH 2 buffer and the phases were separated. The
aqueous phase was further extracted with CH2Cl2 (3 x 3 mL), and the combined organic
extracts were dried over Na2SO4 and concentrated in vacuo to give a yellow gum. This was
purified by silica chromatography (50% EtOAc: pet. ether) to give ketone 24 as a bright
white solid (37 mg, 0.57 mmol, 65%); m.p. 145-146 °C; 27][ D -31 (c = 0.52, CHCl3); υ
max/cm-1 (neat) 3406 (NH), 1739 (ester C=O), 1670 (ketone C=O), 1628 (amide C=O), 1511
(NH); δH (400 MHz, CDCl3) 8.25 (1H, s, C29-H), 8.00 (1H, s, C32-H), 7.59 (1H, d, J 9.5 Hz,
N4-H), 7.50 (1H, d, J 9.0 Hz, N19-H), 5.13 (1H, dd, J 9.5, 6.5 Hz, C5-H), 4.74 (1H, dd, J 9.0,
6.0 Hz, C20-H), 3.75 - 3.82 (3H, m, OCH3), 3.59 (1H, spt, J 7.0 Hz, C23-H), 2.91 (3H, s,
C30-CH3), 2.73 - 2.79 (3H, m, C30-CH3), 2.31 - 2.45 (1H, m, C26-H), 1.93 - 2.09 (1H, m,
C35-H), 1.51 - 1.63 (1H, m, C37-H), 1.25 - 1.36 (1H, m, C37-H), 1.18 (3H, d, J 6.5 Hz, C25-
H3), 1.15 (3H, d, J 7.0 Hz, C25-H3), 0.94 - 1.03 (12H, m, C27-H3, C28-H3, C36-H3, C38-H3);
δC (125 MHz, CDCl3) 201.5 (C2), 172.3 (C21), 164.0 (C6), 162.3 (C12), 161.6 (C3), 159.5
(C18), 154.3 (C15), 153.6 (C33), 153.1 (C9), 148.3 (C30), 143.8 (C14), 138.7 (C29-H),
130.9 (C11), 130.2 (C8), 130.0 (C17), 120.2 (C32-H), 56.1 (C20-H), 53.0 (C5-H), 52.1
(CO2CH3), 38.0 (C35-H), 34.3 (C23-H), 32.9 (C26-H), 25.3 (C37-H2), 18.9, 18.2, 17.8, 17.7
(C24, C25, C27, C28, C36), 12.2, 11.9, 11.5 (C30-CH3, C33-CH3, C38); m/z (ESI+) 677.1
([M+Na] 100%); HR ESI, m/z = 677.2352, (C31H38N6O8SNa requires M+Na = 677.2364).
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Azolemycin A 1a and Azolemycin B 1b
Hydroxylamine hydrochloride (3.0 mg, 0.04 mmol) and pyridine (3.3 μL, 0.04 mmol) were 
added to a stirred solution of the ketone 24 (9 mg, 0.01 mmol) in MeOH (0.6 mL) and CHCl3
(0.6 mL) under a nitrogen atmosphere. After 6 hours at room temperature, additional
hydroxylamine hydrochloride (3.0 mg, 0.04 mmol) and pyridine (3.3 μL, 0.040 mmol) were 
added and the reaction was stirred at room temperature overnight. The reaction mixture was
reduced in vacuo and the residue partitioned between pH 4 buffer (5 mL) and CH2Cl2, and
the phases were separated. The aqueous phase was further extracted with CH2Cl2 (3 x 2 mL)
and the combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give
the crude oxime. This was purified by silica chromatography (50% EtOAc: pet ether) to give
azolemycins A and B, 1, as a mixture of E/Z geometric isomers (major isomer azolemycin A,
minor isomer azolemycin B; 8 mg, 0.012 mmol, 85 %); 25][ D +6.1 (c = 0.17, CHCl3); υ
max/cm-1 (neat) 3402 (NH), 3316-3274 (broad, O-H), 1741 (ester C=O), 1668 (C=N), 1629
(amide C=O), 1513 (NH); δH (700 MHz, CDCl3) 9.37 (1H, br. s., NOH), 8.26 (1H, m, C29-
H), 8.00 (1H, m, C32-H), 7.60 (1H, d, J 10.0 Hz, N4-H), 7.51 (1H, d, J 9.0 Hz, N19-H), 5.25
(1H, dd, J 10.0, 6.0 Hz, C5-H), 4.75 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.78 (3H, s, OCH3), 3.50
(1H, sept, J 7.0 Hz, C23-H), 2.90 (3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.36 - 2.30 (1H,
m, C26-H), 2.05 – 1.99 (1H, m, C35-H), 1.57 (1H, dqd, J 15.0, 7.5 Hz, 5.0 Hz, C37-H2), 1.31
(1H, d, J 7.5 Hz, C25-CH3), 1.30 – 1.23 (4H, m, C25-H3, C37-H2), 1.02 (3H, d, J 7.0 Hz,
C28-CH3), 1.00 (3H, d, J 7.0 Hz, C28-CH3), 0.98 (3H, d, J 7.0 Hz, C36-CH3), 0.97 (3H, t, J
7.5 Hz, C38-CH3); Minor stereoisomer peaks at 5.34 (1H, dd, J 9.0, 6.0 Hz, C5-H), 2.97 -
3.02 (1H, m, C23-H), 2.43 - 2.37 (1H, m, C26-H), 1.19 - 1.17 (3H, m, C25-CH3), 1.15 - 1.17
(1H, m, C25-CH3); δC (175 MHz, CDCl3) 172.3 (C21), 165.6 (C6), 163.8 (C3), 162.3 (C12),
161.6 (C18), 158.8 (C2), 154.3 (C15), 153.7 (C33), 152.9 (C9), 148.3 (C30), 143.8 (C14),
138.6 (C29-H), 130.9 (C11), 129.9, 129.8 (C17, C8), 120.2 (C32-H), 56.2 (C20-H), 52.6 (C5-
H), 52.1 (CO2CH3), 38.0 (C35-H), 32.9 (C26-H), 25.8 (C23-H), 25.3 (C37-H2), 18.9, 18.7,
18.5, 18.3, 15.6 (C24, C25, C27, C28, C36), 12.1, 11.8, 11.5 (C30-CH3, C33-CH3, C38); m/z
(ESI-) 668.2 ([M-H] 100%); HR ESI, m/z = 668.2470, (C31H38N7O8S requires M-H =
668.2508), m/z = 692.2479, (C31H39N7O8SNa requires M+Na = 692.2473). The data are
consistent with the natural product.
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Azolemycin C 2a and Azolemycin D 2b
Methoxyamine hydrochloride (3.8 mg, 0.046 mmol) and pyridine (3.7 μL, 0.046 mmol) were 
added to a stirred solution of ketone 24 (10 mg, 0.015 mmol) in MeOH (0.5 mL) and CHCl3
(0.2 mL) under a nitrogen atmosphere. After 4 hours, the reaction mixture was reduced in
vacuo and the residue partitioned between pH 4 buffer (3 mL) and CH2Cl2 (2 mL). The
phases were separated and the aqueous phase further extracted with CH2Cl2 (3 x 2 mL). The
combined organic extracts were dried over Na2SO4 and concentrated in vacuo. Azolemycins
C 2a (minor isomer) and D 2b (major isomer) were obtained, as a mixture, by silica
chromatography (50% EtOAc: pet. ether) as a white solid (9 mg, 0.013 mmol, 87 %); 21][ D
+27.6 (c = 0.12, CHCl3); υ max/cm-1 (neat) 3414 (NH), 1741 (ester C=O), 1672 (C=N), 1630
(amide C=O), 1509 (NH); δH (400 MHz, CDCl3), 2b: 8.24 (1H, s, C29-H), 8.00 (1H, s, C32-
H), 7.51 (1H, d, J 9.0 Hz, N19-H), 7.36 (1H, d, J 8.5 Hz, N4-H), 5.29 (1H, dd, J 8.5, 6.5 Hz,
C5-H), 4.75 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.95 (3H, s, NOCH3), 3.78 (3H, s, CO2CH3),
2.98 (1H, sept, J 7.0 Hz, C23-H), 2.91 (3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.42 - 2.32
(1H, m, C26-H), 2.00 – 1.89 (1H, m, C35-H), 1.52 – 1.45 (1H, m, C37-H2), 1.36 - 1.25 (3H,
m, C37-H2), 1.16 (3H, d, J 7.0 Hz, C25-H3), 1.14 (3H, d, J 7.0 Hz, C25-H3), 1.05 - 0.94
(12H, m, C36-CH3,C38-CH3, C28-CH3, C28-CH3); Minor stereoisomer peaks at 5.18 (1H,
dd, J 9.5, 7.0 Hz, C5-H), 4.00 (3H, s, NOCH3), 3.45 - 3.35 (1H, m, C23-H), 1.23 (3H, d, J 7.0
Hz, C25-CH3), 1.22 (3H, d, J 7.0 Hz, C25-CH3); During the time taken to resubmit the
compound for further NMR experiments, the sample isomerized to give predominately the E-
geometric isomer, azolemycin C 2a. δH (700 MHz, CDCl3) 8.24 (1H, s, C29-H), 8.00 (1H, s,
C32-H), 7.51 (1H, d, J 9.0 Hz, N19-H), 7.27 – 7.27 (1H, m, N4-H), 5.18 (1H, dd, J 9.0, 7.0
Hz, C5-H), 4.75 (1H, dd, J 9.0, 5.5 Hz, C20-H), 4.00 (3H, s, NOCH3), 3.78 (1H, s, CO2CH3),
3.40 (1H, sept, J 7.0 Hz, C23-H), 2.91 (3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.35 (1H,
oct, J 7.0 Hz, C26-H), 2.05 - 1.99 (1H, m, C35-H), 1.60 - 1.53 (1H, m, C37-H2), 1.33 - 1.26
(1H, m, C37-H2), 1.23 (3H, d, J 7.0 Hz, C25-H3), 1.22 (3H, d, J 7.0 Hz, C25-H3), 1.03 (3H,
d, J 7.0 Hz, C28-CH3), 1.00 (3H, d, J 6.5 Hz, C28-CH3), 0.97 (3H, t, J 7.5 Hz, C38-H3), 0.96
(3H, d, J 6.5 Hz, C35-H3); δC (175 MHz, CDCl3) 172.3 (C21), 165.1 (C6), 162.7 (C3), 162.3
(C12), 161.6 (C18), 157.1 (C2), 154.3 (C15), 153.6 (C33), 153.3 (C9), 148.3 (C30), 143.8
(C14), 138.6 (C29-H), 130.8 (C11), 130.0, 129.9 (C17, C8), 120.1 (C32-H), 63.0 (NOCH3),
56.1 (C20-H), 52.6 (C5-H), 52.1 (CO2CH3), 38.0 (C35-H), 33.0 (C26-H), 25.9 (C23-H), 25.3
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(C37-H2), 19.0, 18.6, 18.5, 15.6 (C24, C25, C27, C28, C36), 12.2, 11.9, 11.5 (C30-CH3, C33-
CH3, C38); m/z (ESI+) 706.2 ([M+H] 100%); HR ESI, m/z = 706.2625, (C32H41N7O8SNa
requires M+Na = 706.2630). The data are consistent with that obtained for the natural
product.
Tetraoxazole Methyl Ester 25
A solution of pentapeptide alcohol 15 (0.10 g, 0.19 mmol) in dry CH2Cl2 (20 mL) was cooled
to -78 ˚C under nitrogen. (Diethylamino)sulfur trifluoride (0.05 mL, 0.4 mmol) was added 
and the reaction mixture was stirred at -78 ˚C for 2 hours, then at room temperature for 30 
minutes. The reaction was quenched with saturated aqueous NaHCO3 solution (10 mL) and
was stirred for a further 15 minutes. The phases were separated and the aqueous phase was
further extracted with CH2Cl2 (2 x 10 mL). The combined organic extracts were dried over
Na2SO4 and concentrated in vacuo to give the crude oxazoline as a bright yellow oil (0.10 g),
which was used immediately without further purification.
A solution of the oxazoline (0.10 g, 0.19 mmol) in CCl4 (0.5 mL), MeCN (0.7 mL) and
pyridine (0.7 mL) was cooled to 0 ˚C under nitrogen. 1, 8-Diazabicyclo[5.4.0]undec-7-ene  
(0.12 mL, 0.81 mmol) was added and the reaction mixture was allowed to reach room
temperature over 72 hours. The reaction mixture was quenched with pH 2 buffer (5 mL) and
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over Na2SO4
and concentrated in vacuo to give the crude oxazole. Purification by silica chromatography (5
% MeOH: CH2Cl2) gave oxazole 25 as a sticky colourless oil (90 mg, 0.17 mmol, 89 %);
25][ D -38 (c = 0.87, CHCl3); υ max/cm-1 (neat) 3330 (NH), 1712 (ester C=O), 1682 (amide
C=O), 1523 (NH); δH (400 MHz, CDCl3) 8.39 (1H, s, C32-H), 8.28 (1H, s, C29-H), 5.32 (1H,
d, J 9.0 Hz, N4-H), 4.84 (1H, dd, J 9.0, 6.0 Hz, C5-H), 3.94 (3H, s, OCH3), 2.83 (3H, s, C30-
CH3), 2.72 (3H, s, C30-CH3), 2.29 - 2.18 (1H, m, C36-H), 1.44 (9H, s, C(CH3)3), 1.02 - 0.91
(6H, m, 2 x C27-H3); δC (100 MHz, CDCl3) 165.5 (C6), 162.5 (C18), 156.7, 156.6 (C12,
C33), 166.4, 154.0, 152.9, 151.3 (CO2tBu, C9, C15, C30), 138.8, 138.6 (C29-H, C32-H),
131.0 (C8), 129.8 (C14), 128.4 (C17), 125.7 (C11), 80.1 (C(CH3)3), 54.3 (C5-H), 52.1
(OCH3), 33.0 (C26-H), 28.3 (C(CH3)3), 18.7, 18.0 (2 x C27-H3), 12.1, 11.9 (C30-CH3, C33-
CH3); m/z (ESI+) 550.1 ([M+Na] 100%); HR ESI, m/z = 550.1909, (C25H29N5O8Na requires
M+Na = 550.1908).
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Tetraoxazole Carboxylic Acid 26
A solution of LiOH (40 mg, 1.7 mmol) in water (1.3 mL) was added to a solution of
tetraoxazole methyl ester 25 (90 mg, 0.17 mmol) in THF (7.5 mL), CH2Cl2, (1.0 mL) and
MeOH (7.5 mL). After 6 hours at room temperature, the reaction mixture was acidified with
pH 2 buffer and the organic solvents removed in vacuo. EtOAc (10 mL) was added and the
phases were separated. The aqueous phase was further extracted with EtOAc (3 x 5 mL) and
the combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give acid
26 as a sticky colourless oil (60 mg, 0.11 mmol, 67 %); 23][ D -16 (c = 0.15, CHCl3); υ max/cm-
1 (neat) 3338 (NH), 3317 (O-H), 1701 (ester C=O), 1655 (amide C=O), 1524 (NH); δH (400
MHz, CDCl3) 8.40 (1H, s, C32-H), 8.30 (1H, s, C29-H), 5.39 (1H, d, J 9.5 Hz, N4-H), 4.86
(1H, dd, J 9.0, 6.0 Hz, C5-H), 2.84 (3H, s, C30-CH3), 2.76 (3H, s, C33-CH3), 2.29 - 2.19 (1H,
m, C26-H), 1.49 - 1.44 (9H, m, C(CH3)3), 0.99 - 0.93 ppm (6H, m, 2 x C27-CH3); δC (100
MHz, CDCl3) 164.6 (C6), 164.1 (CO2H), 156.5 (C33), 155.8 (C12), 154.4, 152.9, 152.0,
150.4 (C9, C11, C15, C30), 137.8, 137.8 (C29-H, C32-H), 129.8 (C14), 128.7 (C8), 127.1
(C17), 124.6 (C11), 79.1 (C(CH3)3), 53.3 (C5-H), 32.0 (C26-H), 27.3 (C(CH3)3), 17.7, 17.0
(2 x C27-CH3), 11.2, 10.9 (C30-CH3, C33-CH3); m/z (ESI+) 536.1 ([M+Na] 100%); HR ESI,
m/z = 536.1751, (C24H27N5O8Na requires M+Na = 536.1752).
Tetraoxazole Hexapeptide 27
A solution of tetraoxazole carboxylic acid 26 (59 mg, 0.11 mmol) and HOBt (88 %, 4 mg,
0.02 mmol) in EtOH (3 mL) was stirred at room temperature for 15 minutes. L-Isoleucine
methyl ester hydrochloride (52 mg, 0.29 mmol) was added and the solution was cooled to 0
˚C. N-Methyl morpholine (0.08 mL, 0.8 mmol) was added followed, after 15 minutes, by
EDCI (33 mg, 0.17 mmol), and the mixture was allowed to reach room temperature
overnight. pH 2 buffer (5 mL) was added and mixture was extracted with EtOAc (5 x 5 mL).
The combined organic extracts were washed with saturated aqueous NaHCO3 solution (5
28
mL), water (5 mL) and brine (5 mL), dried over Na2SO4 and concentrated in vacuo.
Purification by silica chromatography (2% MeOH: CH2Cl2) gave the hexapeptide 28 as a
clear pale yellow oil (38 mg, 0.060 mmol, 54 %); 28][ D -18 (c = 0.56, CHCl3);  υ max/cm-1
(neat) 3346 (NH), 3317 (O-H), 1739 (ester C=O), 1667 (amide C=O), 1511 (NH); δH (600
MHz, CDCl3) 8.30, 8.29 (1H, s, C29-H; 1H, s, C32-H), 7.47 (1H, d, J 9.0 Hz, N19-H), 5.32
(1H, d, J 9.0 Hz, N4-H), 4.85 (1H, dd, J 9.0, 6.0 Hz, C5-H), 4.73 (1H, dd, J 9.0, 5.3 Hz, C20-
H), 3.77 (3H, s, OCH3), 2.86 (3H, s, C30-CH3), 2.72 (3H, s, C33-CH3), 2.28 - 2.21 (1H, m,
C26-H), 2.04 - 1.96 (1H, m, C35-H), 1.55 (1H, dqd, J 13.0, 8.0, 4.5 Hz, C37-H2), 1.45 (9H, s,
C(CH3)3), 1.33 - 1.25 (1H, m, C37-H2), 1.02 - 0.93 (12H, m, 2 x C27-H3, C36-H3, C38-H3);
δC (150 MHz, CDCl3) 172.2 (C21), 165.5 (C6), 161.4 (C18), 156.9 (C12), 155.4 (CO2tBu),
154.0, 153.7 (C9, C30), 151.9, 151.4 (C15, C33), 138.8, 138.3 (C29-H, C32-H), 131.1,
129.9, 129.7 (C8, C14, C17), 125.7 (C11), 80.1 (C(CH3)3), 56.1 (C20-H), 54.3 (C5-H), 52.1
(OCH3), 38.0 (C35-H), 33.0 (C26-H), 28.3 (C(CH3)3), 25.3 (C37-H2), 18.7, 18.0 (2 x C27-
H3), 15.6 (C36-H3), 12.0, 11.8 (C30-CH3, C33-CH3), 11.5 (C38-H3); m/z (ESI+) 663.2
([M+Na] 100%); HR ESI, m/z = 658.3196, (C31H44N7O9 requires M+NH3 = 658.3195).
Tetraoxazole Alcohol 28
Tetraoxazole 27 (38 mg, 0.060 mmol) was dissolved in a solution of acetyl chloride (0.12
mL, 1.8 mmol) and MeOH (0.8 mL), and the reaction mixture stirred at room temperature for
2 hours. The reaction mixture was concentrated in vacuo to give the deprotected amine as the
hydrochloride salt. m/z (ESI+) 563.1 ([M+Na] 100%); HR ESI, m/z = 563.2237,
(C26H32N6O7Na requires M+Na = 563.2225).
A solution of the alcohol 22 (14 mg, 0.12 mmol) and HOBt (88 %, 3 mg, 0.02 mmol) in
EtOH (3 mL) was stirred at room temperature for 10 minutes and added to the deprotected
amine (0.06 mmol). The mixture was cooled to 0 ˚C, and N-methyl morpholine (0.04 mL,
0.38 mmol) was added. After 15 minutes, EDCI (30 mg, 0.14 mmol) was added and the
reaction mixture was stirred for 18 hours. pH 2 buffer (3 mL) and EtOAc (3 mL) were added
and the phases were separated. The aqueous phase was further extracted with EtOAc (3 x 3
mL), and the combined organic extracts were washed with brine (3 mL) and dried over
Na2SO4. The alcohol 28 was obtained by silica chromatography (2 % MeOH: EtOAc) as a
clear oil (24 mg, 0.037 mmol, 62 %); 28][ D -39.4 (c = 0.34, CHCl3); υ max/cm-1 (neat) 3408
(NH), 2966 (O-H), 1740 (ester C=O), 1665 (amide C=O), 1515 (NH); δH (700 MHz, CDCl3)
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8.30 (1H, s, C32-H), 8.27 (1H, s, C29-H), 7.48 (1H, d, J 9.0 Hz, N19-H), 7.37 (1H, d, J 9.0
Hz, N4-H), 5.21 (1H, dd, J 9.0, 6.0 Hz, C5-H), 4.73 (1H, dd, J 9.0, 5.5 Hz, C20-H), 4.10 -
4.15 (1H, m, C2-H), 3.77 (3H, s, OCH3), 3.30 (1H, br. s., OH), 2.85 (3H, s, C30-CH3), 2.72
(3H, s, C33-CH3), 2.34 (1H, oct, J 7.0 Hz, C26-H), 2.28 - 2.21 (1H, m, C23-H), 2.03 – 1.97
(1H, m, C35-H), 1.59 - 1.53 (1H, m, C37-H2), 1.33 - 1.27 (1H, m, C37-H2), 1.07 – 0.90 (18H,
m, 2 x C24-H3, 2 x C27-H3, C36-H3, C38-H3); δC (150 MHz, CDCl3) 173.5 (C3), 172.2
(C21), 165.3 (C6), 161.4 (C18), 156.8 (C12), 153.9, 153.7 (C15, C33), 151.8, 151.4 (C9,
C30), 138.9 (C29-H), 138.4 (C32-H), 131.1 (C14), 130.0, 129.7 (C8, C17), 125.6 (C11), 76.5
(C2-H), 56.2 (C20-H), 52.3, 52.1 (C5-H, OCH3), 37.9 (C35-H), 32.6 (C26-H), 31.7 (C23-H),
25.3 (C37-H2), 19.2, 18.7, 18.2, 15.9, 15.6 (2 x C27-H3, 2 x C24-H3, C36-H3), 12.0, 11.8
(C30-CH3, C33-CH3), 11.5 (C38-H3); m/z (ESI+) 663.2 ([M+Na] 100%); HR ESI, m/z =
663.2754, (C31H40N6O9Na requires M+Na = 663.2749).
Tetraoxazole Ketone 29
A solution of alcohol 28 (24 mg, 0.037 mmol) in dry CH2Cl2 (1.5 mL) and dry DMSO (0.03
mL, 0.4 mmol) was stirred at 0 ˚C under N2. Diisopropylethylamine (0.05 mL, 0.30 mmol)
was added, followed by SO3. pyridine complex (35 mg, 0.22 mmol) and the reaction mixture
was held at 0 ˚C for 6 hours. The reaction mixture was quenched with pH 2 buffer and the 
phases were separated. The aqueous phase was further extracted with CH2Cl2 (5 x 3 mL) and
the combined organic extracts were dried over Na2SO4 and concentrated in vacuo. Ketone 29
was obtained by silica chromatography as a clear, colourless oil (17 mg, 0.027 mmol, 72 %);
25][ D -28 (c = 0.87, CHCl3); υ max/cm-1 (neat) 3401 (NH), 1740 (ester C=O), 1675 (ketone
C=O), 1662 (amide C=O), 1513 (NH); δH (400 MHz, CDCl3) 8.30 (1H, s, C29-H), 8.291H, s,
(1H, s, C32-H), 7.57 (1H, d, J 9.0 Hz, N4-H), 7.46 (1H, d, J 9.0 Hz, N19-H), 5.11 (1H, dd, J
9.5, 7.0 Hz, C5-H), 4.72 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.79 (3H, s, O (CH3), 3.58 (1H, spt,
J 7.0 Hz, C23-H), 2.85 (3H, s, C30-CH3), 2.74 - 2.70 (3H, m, C33-CH3), 2.35 (1H, oct, J 7.0
Hz, C26-H), 2.06 - 1.94 (1H, m, C35-H), 1.62 - 1.49 (1H, m, C37-H2), 1.34 - 1.22 (1H, m,
C37-H2), 1.17 (3H, d, J 6.5 Hz, C24-H3), 1.14 (6 H, d, J 7.0 Hz, C24-H3), 1.02 - 0.93 (12H,
m, 2 x C27-H3, C36-H3, C38-H3); δC (100 MHz, CDCl3) 201.5 (C2), 172.2 (CO2Me), 163.9
(C6), 161.4 (C18), 159.5 (C3), 156.9 (C12), 153.7, 151.9, 151.5 (C9, C15, C30, C33), 139.0
(C32-H), 138.3 (C29-H), 131.1, 130.1, 129.9 (C8, C14, C17), 125.7 (C11), 56.2, (C20-H),
53.0 (C5-H), 52.1 (OCH3), 38.0 (C35-H), 34.3 (C23-H), 32.8 (C26-H), 25.3 (C37-H2), 18.2,
17.7, 17.6, 15.6 (2 x C27-H3, 2 x C24-H3, C36-H3), 12.0, 11.8 (C30-CH3, C33-CH3), 11.5
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(C38-H3); m/z (ESI+) 661.1 ([M+Na] 100%); HR ESI, m/z = 661.2606, (C31H38N6O9Na
requires M+Na = 661.2592).
Tetraoxazole Analogue 30
Pyridine (13 µL, 0.017 mmol) and hydroxylamine hydrochloride (12 mg, 0.017 mmol) were
added to a solution of the ketone 29 (17 mg, 0.027 mmol) in MeOH (0.6 mL) and CHCl3 (0.6
mL). The reaction mixture was stirred under nitrogen for 18 hours, and then concentrated in
vacuo. The residue was partitioned between CH2Cl2 (5 mL) and pH 4 buffer (5 mL). The
phases were separated and the aqueous phase was further extracted with CH2Cl2 (3 x 2 mL).
The combined organic extracts were dried over sodium sulfate and concentrated in vacuo.
The tetraoxazole analogue of azolemycin B, 30, was obtained as a mix of E/Z geometric
isomers by silica chromatography (50 % EtOAc: pet. ether) as a clear colourless oil (Major
isomer assumed to be Z by comparison with azolemycins A and B; 6 mg, 0.009 mmol, 33 %
of both isomers); 28][ D +1.6 (c = 0.19, CHCl3); υ max/cm-1 (neat) 3394 (NH), 3304 (OH), 1740
(ester C=O), 1665 (C=N), 1513 (NH); Major geometric Z-isomer peaks δH (700MHz, CDCl3)
8.31 (1H, s, C29-H), 8.30 (1H, s, C32-H), 7.51 (1H, d, J 8.4 Hz, N4-H), 7.48 (1H, d, J 9.2
Hz, N19-H), 5.32 (1H, dd, J 8.8, 6.2 Hz, C5-H), 4.74 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.77
(1H, s, OCH3), 3.01 (1H, sept, J 6.9 Hz, C23-H), 2.86 (1H, s, C30-CH3), 2.73 (1H, s, C33-
CH3), 2.38 (1H, oct, J 6.2 Hz, C26-H), 2.05 - 1.98 (1H, m, C35-H), 1.60 - 1.52 (1H, m, C37-
H2), 1.35 - 1.21 (1H, m, C37-H2), 1.17 (3H, d, J 6.6 Hz, C24-H3), 1.15 (3H, d, J 7.0 Hz, C24-
H3), 1.03 – 0.99 (9H, m, 2 x C27-H3, C33-H3), 0.97 (3H, t, J 7.3 Hz, C38-H3); Minor
geometric E-isomer peaks at 5.20 (1H, dd, J 9.2, 6.6 Hz, C5-H), 3.51 - 3.46 (1H, m, C23-H),
2.34 – 2.29 (1H, m, C26-H); δC (175MHz, CDCl3) 172.2 (C21), 164.6 (C6), 161.8 (C18),
161.5 (C3), 157.6 (C2), 156.9 (C9), 153.8, 153.7 (C12, C33), 151.9, 151.5 (C15, C30), 139.0
(C29-H), 138.3 (C32-H), 131.1 (C17), 129.9, 129.8 (C8, C14), 125.7 (C11), 56.1 (C20-H),
52.9 (C5-H), 52.1 (OCH3), 38.0 (C35-H), 32.8 (C26-H), 30.9 (C23-H), 25.3 (C37-H2), 20.0,
19.8 (2 x C24-H3), 18.9, 18.4 (2 x C27-H3), 15.6 (C36-H3), 12.0, 11.8 (C30-CH3, C33-CH3),
11.5 (C38-H3); m/z (ESI+) 675.9 ([M+Na] 100%); HR ESI, m/z = 767.2697, (C31H39N7O9Na
requires M+Na = 676.2701).
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Comparison of Natural and Synthetic Azolemycin A E isomer 1H and 13C NMR
Natural Product E Synthesised Product
C/N positions 1H (ppm, J Hz) 13C (ppm) 1H (ppm, J Hz) 13C (ppm)
1 1.28 (d, 7.0) 18.8 1.31 (d, 7.0) 18.7
2 1.25 (d, 7.0) 18.2 1.26 (d, 7.0) 18.3
3 3.47 (m) 25.6 3.50 (sept., 7.0) 25.8
4 158.8 158.8
N-OH 10.02 (s, b) 9.37 (s, b)
5 163.5 163.8
NH 7.65 (b) 7.60 (d, 10.0)
6 5.25 (dd, 6.5, 8.7) 52.7 5.25 (6.2, 9.4) 52.6
7 2.30 (m) 33.0 2.33 (oct, 6.6) 32.9
8/9 0.98 (d, 6.7) 19.0 1.00 (d, 6.8) 18.9
8/9 1.00 (d, 6.7) 18.4 1.02 (d, 6.9) 18.5
10 165.4
11 129.8




15-Me 2.89 (s) 12.2 2.90 (s) 12.1
16 162.2 162.3
17 143.9 143.8




21-Me 2.74 (s) 11.8 2.75 (s) 11.8
22 161.6 161.6
NH 7.52 (d, 8.8) 7.51 (d, 9.0)
23 4.73 (dd, 5.4, 8.8) 56.3 4.75 (dd, 5.6, 8.9) 56.2
24 172.2 172.3
25 2.00 (m) 37.9 2.02 (m) 38.0
26 1.28/1.56 (m) 25.6 1.30 (m)/1.57 (dqd, 4.8,
7.5, 14.9)
25.3
27 0.96 (t, 7.4) 11.5 0.97 (t, 7.5) 11.5
28 0.97 (d, 6.3) 15.6 0.98 (d, 6.7) 15.6

















































Z- isomer, Azolemycin D





























































































































































Comparison of Natural and Synthetic Azolemycin D Z-isomer 1H NMR
Natural Synthetic
C/N positions 1H (ppm, J Hz) 1H (ppm, J Hz)
1 1.14 (d, 7.0) 1.13 (d, 6.9)
2 1.15 (d, 7.0) 1.15 (d, 7.0)
3 2.97 (m) 2.96 (sept., 6.8)
4
N-O-Me 3.95 (s) 3.94 (s)
5
NH 7.38 (d, 8.9) 7.35(d, 9.0)
6 5.28 (dd, 6.4, 8.9) 5.28(dd, 6.4, 8.8)
7 2.35 (m) 2.36(m)
8 1.00 (d, 6.7) 0.99(d, 6.8)
















NH 7.51(d, 8.6) 7.50(d, 8.8)
23 4.74 (dd, 5.4, 8.6) 4.74 (dd, 5.6, 9.0)
24
25 2.00 (m) 2.00 (m)
26 1.28/1.56(m) 1.29/1.56(m)
27 0.96(t, 7.4) 0.96(t, 7.2)


















































Comparison of Natural and Synthetic Azolemycin C E-isomer 1H and 13C NMR
Natural Product Synthetic Product
C/N positions 1H (ppm, J Hz) 13C (ppm) 1H (ppm, J Hz) 13C (ppm)
1 1.24 (d, 7.0) 18.5 1.21 (d, 7.1) 18.6
2 1.20 (d, 7.0) 18.4 1.19 (d, 7.0) 18.5
3 3.39 (m) 25.6 3.38 (sept., 7.0) 23.9
4 157.6 157.1
N-O-Me 3.99 (s) 62.7 3.98 (s) 63.0
5 162.8 162.7
NH 7.29 (d, 8.8) 7.48 (d, 9.0)
6 5.19 (dd, 6.4, 8.8) 52.6 5.16 (dd, 7.2, 9.4) 52.6
7 2.30 (m) 32.9 2.33 (oct., 6.8) 33.0
8 0.98 (d, 6.7) 19.0 0.98(d, 6.8) 19.0
9 1.00 (d, 6.7) 18.4 1.00 (d, 6.8) 19.0
10 165.3 165.1
11 129.8 129.9




15-Me 2.88 (s) 11.8 2.89 (s) 12.2
16 161.9 162.3
17 143.9 143.8




21-Me 2.74 (s) 11.4 2.73(s) 11.9
22 161.7 161.6
NH 7.51 (d, 8.7) 7.25 (d, 9.0)
23 4.74 (dd, 5.4, 8.7) 56.1 4.73 (dd, 5.7, 9.0) 56.1
24 172.1 172.3
25 2.00 (m) 37.9 1.99 (m) 38.0
26 1.28/1.56 (m) 25.4 1.28/1.56(m) 25.3
27 0.96 (t, 7.4) 11.6 0.95 (t, 7.4) 11.5
28 0.97 (d, 6.3) 15.5 0.95 (d, 6.8) 15.6
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